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INTRODUCTION
By Carolyn S. Leach, Ph. D.
In October, 1970, the first conference on endocrine data collected
in support of manned space flight was conducted at the NASA Manned Space-
craft Center, Houston, Texas. As a part of the continuing effort to
fully understand and to evaluate the endocrine changes observed during
previous manned missions and, thereby, to further understanding of the
physiological adaptation of man to the space-flight environment, the
Second Annual NASA Manned Spacecraft Center Endocrine Program Conference
vas conducted in December, 1971. Investigators reported on vork perti-
nent to the overall program developed in support of the Apollo missions
and the long-duration Skylab flights.' The goals of this program continue
to be of utmost importance and, indeed, the relevance" of these goals has
been augmented as man further extends himself and his technology into
space. For the purpose of review, these goals are restated here.
1. The establishment (and continuation) of an operational laboratory
for immediate endocrinologic assays at the NASA Manned Spacecraft Center
2. The assembly of a group of endocrine experts who are qualified
to advise on procedures and the interpretation of data
3- The advancement of the field of endocrinology by the application
of analytical procedures that are low in sample-volume requirements but
that are high in specificity
The attendees of this Second Annual NASA Manned Spacecraft Center
Endocrine Program Conference consisted of those who were chosen to help
conduct the program. Each participant presented a discussion of work
in his area of specialization and related his contributions in support
of the program, either with respect to studies or to the development of
methodology. The tape-recorded transcripts of these presentations were
submitted to the authors for editing and then were compiled into these
proceedings.
IV
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1. ENDOCRINE LABORATORY RESULTS
APOLLO MISSIONS lU and 15
By Carolyn S. Leach, Ph. D.
INTRODUCTION
During the year since the last Manned Spacecraft Center endocrine
conference, the endocrine laboratory has continued its major role in
support of the NASA manned space flights. Because all of the flight
data through Apollo 13 were reviewed at the conference last year (ref. l),
this report will discuss the two missions (Apollo lU and 15) that have
occurred in the interim. Although both missions were lunar landing
missions of approximately the same duration and both involved three
crewmen, there were fundamental differences in the mission parameters
(table I.). It is still an open question as to whether these differences
influenced the mission medical results; however, there is no doubt that
the Apollo 15 crewmen reacted to space flight differently than did the
crewmen of previous missions.•
Both Apollo lU and 15 were successful in their basic objectives of
lunar exploration and physical science research experiments (refs. 2
and 3). The biomedical information is obtained for the purpose of ensur-
ing crewmember safety and for obtaining information on the biomedical '
effects of space flight. The medical results from these two flights were
more detailed than the data obtained on any previous Apollo flights,
facilitating a more complete interpretation of the physiological effects
of space flight.
The endocrine laboratory participated in the medical examination
of the crewmen by the collection of biological samples and their analyses
in order to determine the effects of space flight on the hormonal com-
pounds that regulate endocrine/metabolic homeostasis.
METHODS
Analyses were performed on U5 cubic centimeters of venous blood that
was drawn 27 (F-2J), 15, and 5 days before the missions in order to as-
certain the health status of the crewmen and to establish baseline values
for postmission comparison. Comparable amounts .of blood were drawn as
1-2
soon as .possible (ASAP) after recovery, 1 day (IT hours), 6- days, and
16 days (+13 on Apollo 15) after recovery on both Apollo lU and 15; in
addition, blood was drawn on the second day after recovery on Apollo 15.
All blood samples were obtained while the crewmembers were fasting,
except for those samples drawn immediately following splashdown (crewmen
had not eaten during the preceding U hours).
Beginning on day 27 pref light, 2U-hour urine samples were collected
from each crewman on the same day that bloofi was drawn. Twenty-four-
hour urine samples were collected 1, 2, 3, and 6 days postf light. These
samples were aliquoted, stabilized, and frozen for later analysis.
Because of the need for crewmen health stabilization, the crewmen
for both Apollo lh and 15 were confined to the NASA John F. Kennedy Space
Center crew quarters Tor health stabilization for the 21 days immediately
preceding the missions and the Apollo 1^ crew, in addition, underwent a
21-day quarantine postf light.
During the pre- and postf light periods , the crewmen consumed the
diet of their choosing but inflight adhered to the provided Apollo diet.
Sodium intake averaged 5 grams per day and potassium intake averaged
3 grams per day. Fluids were available ad libitum.
Analyses on the blood (plasma or serum) samples included hydrocorti-
sone, triiodothyronine (T ) , thyroxine (T,), angiotensin I, insulin,
parathormone , sodium, potassium, chloride, osmolality, and others. In
addition, adrenocorticotrophic hormone (ACTH) was measured in the samples
from the Apollo 15 crewmen.
The 24-hour urine samples were analyzed for hydrocortisone , epineph-
rine, norepinephrine , antidiuretic hormone (ADH) , aldosterone, sodium,
potassium, chloride, and osmolality. In addition, the samples from the
Apollo 15 crewmen were analyzed for 17-ketosteroid and titrat'able acidity.
Results and Discussion: Apollo ih
In the assessment of the endocrine/fluid electrolyte status of the
Apollo lU crewmen, the two areas emphasized were endocrine-metabolic
cost and endocrine control of fluid balance. The plasma/serum results
from Apollo ih are given in table II, and the 2^-hour urine results are
given in table III. The results from Apollo 1^ were similar to those
results from the previous Apollo, missions and further support the pre-
viously proposed hypothesis regarding endocrine/fluid electrolyte re-
sponses both to space flight and to return to 1-g (ref. U). However,
several points deserve specific mention.
1-3
During the preflight phase, all three crewmen were affected by a
stress of undetermined origin that was sufficient to cause a catecholamine
and hydrocortisone response. This was significant because these hormones
are responsible for many metabolic processes. Consequently, these ele-
vated hormone levels necessitated an interpretation of the preflight
medical data, with consideration given to these abnormal values.
Immediately postflight, there was a decrease in plasma hydrocortisone
similar to that noted in previous missions. Several explanations have
been proposed for this phenomenon. Among these are a reduction in adrenal
glucocorticoid activity induced by weightlessness or, more likely, changes
in metabolism of the steroids that were caused by alteration in liver
blood flow. Plans for future Apollo missions include additional urine
and plasma assays for specific compounds that will help resolve this
problem. However, no definitive information will be available until
inflight urine samples collected during Skylab missions are returned for
analysis.
The analysis conducted to ascertain metabolic response to the con-
ditions of space flight included T_, T, , and insulin. Although it was
not possible to analyze for these hormones at each sample period, it is
evident that no significant changes occurred when the postflight results
are compared to the preflight results. Furthermore, insulin concentra-
tion did not differ significantly in the comparison of the ASAP results
to the preflight values.
Parathormone was considered in relation to calcium and phosphorus
metabolism. The concentration of this hormone was not significantly
different during the postflight period, although there appeared to be a
decreasing concentration trend.
In determinations of the fluid/electrolyte status of the three
crewmen, it was noted that the lunar module pilot (LMP) and command
module pilot (CMP) showed changes of greater magnitude than the commander
(CDR). From the graphs depicting these data, it can be observed that
the LMP and CMP showed a decrease in 2ii-hour urine volume postflight
(fig. l). This finding, in conjunction with the determinations for the
electrolytes sodium (Na), potassium (K), and cloride (Cl) and with the
endocrine results, suggest a retention in fluids and electrolytes (fig. 2).
Although the CDR showed a slight general increase in aldosterone, he
reacted to a much lesser degree than the other two crewmen (fig. 3). The
increase in aldosterone is suggestive of renal tubular activity to
maintain sodium homeostasis. Angiotensin I, a measure of renin activity,
was elevated significantly only in the CMP postflight (fig. h).
In summary, two distinct patterns of response to space flight can
be observed in the crewmen of Apollo ih. Although the CMP was
considerably more reactive than either of the other two crewmen, both he
and the IMP were characterized by significant changes in all relevant
parameters measured. The CDR seemed nonreactive to the environmental
and physiological stresses associated with space flight and essentially
remained in a compensated state. The marked changes of the CMP postflight
that were made in an attempt to adapt to the absence of gravity or
reintroduction to earth gravity, were reflective of increased homeostatic
activity. These data support further the hypothesis of this laboratory
that the physiological cost of adaptation may, in some instances, exceed
the available reserves, thereby progressing to a state that becomes
clinically important.
Results and Discussion: Apollo 15
The results of the plasma analyses from crewmen of Apollo 15
shown in table IV, and the 2U-hour urine results are given in table V.
Plasma hydrocortisone was elevated on F-5 in the CDR and IMP; however,
as found in previous missions, the immediate postflight concentration
appeared to be decreased in two crewmen and not changed in the third.
ACTH was measured, and the findings ranged from normal to decreased for
the three crewmen immediately postflight. The 2^ -hour urine results
showed elevations in hydrocortisone during the first few days postflight.
These findings have been relatively constant for the Apollo flight
(ref. 5) and are unexplained. It is thought that steroid metabolism may
not be normal during space flight. This would account for the postflight
changes if there was an immediate reaction to the effects of gravity by
changes in blood flow to the adrenal, liver, and kidney.
The catecholamines demonstrated significant elevations in all three
crewmen during the postflight period. These elevations occurred generally
on the same days as those observed for hydrocortisone; the two different
compounds (steroids and catecholamines) are indicative of both adrenal
cortical response to stress and the reaction of the sympathetic nervous
system to the condition imposed on the crewmen as part of the readapta-
tion to the earth environment.
Insulin and T were measured as indicators of metabolic activity
before and after space flight. There were no significant changes in
T or in insulin in the CDR or CMP. Immediately after recovery, the
IMP exhibited an elevated insulin level that returned to preflight values
by the next sampling period. This is not thought to be related to food
consumed by this crewman prior to recovery because the blood glucose was
normal. It could have been a response to stress.
Parathormone analysis demonstrated no significant changes in the
three crewmen. These results are consistent with other studies on these
1-5
men that demonstrated no change in calcium or phosphorus excretion post-
flight. Furthermore, there were no changes in bone mineral mass as
measured by photon absorptometry on this mission (ref. 6), indicating
no change in body composition.
The electrolyte and osmolality analyses were conducted by the
clinical laboratory in support of the operational medicine work as well
as for a specific fluid/electrolyte study. Serum sodium was unchanged
postflight in the CDR and IMP, but the CMP showed a slight decrease
postflight when compared to preflight values. Serum chloride remained
unchanged in all three crewmen. However, serum potassium was decreased
significantly immediately postflight in all three crewmen (figs. 5 and 6).
Twenty-four hour urine electrolyte data demonstrated a retention
of Na, K, and Cl postflight (fig. 7) that had volumes ranging from normal
to increased (fig. 8). The urine had increased titratable acidity and
the osmolality was decreased slightly; immediately postflight, urinary
antidiuretic hormone levels were normal to slightly elevated (fig. 9).
Renin activity was measured as angiotensin I in the blood samples
pre- and postflight. Although these postflight results did not differ
statistically from the preflight analysis, there is an apparent increase
postflight. This increase is substantiated by the significant postflight
increase in urinary aldosterone (fig. 10) , which is thought to be con-
tributory to the decrease in serum K observed on this mission (fig. 6).
The hormonal fluid/electrolyte data discussed above give evidence
of inflight changes in body fluid and electrolyte balance initiated
by the null gravity environment. Redistribution of the circulating blood
volume, particularly from the lower extremities into the abdomen and
thorax, results in a negative water balance with a net loss of water and
electrolytes. Dietary intake of electrolytes cannot be ignored in con-
sideration of fluid/electrolyte loss because it has been variable;
however, the sodium and potassium intakes during this mission appear to
be on the lower side of normal daily intakes.
The loss of fluid/electrolytes is thought to occur early in space
flight, just as In bedrest, and depletes the plasma volume that is then
replenished by an aldosterone response. During flight, an increase in
aldosterone would account for the decrease in exchangeable potassium
measured during this mission.
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CONCLUDING REMARKS
Endocrine/metabolic responses to space flight have "been measured on
the crewmen of Apollo missions lU and 15- There were significant bio-
chemical changes on the crewmen of both missions immediately postflight.
However, the Apollo 15 mission results differed from Apollo 1^ and pre-
vious Apollo missions by the apparent lack of fluid conservation post-
flight shown by a normal to increased urine volume with slight increases
in antidiuretic hormone. The exact .reasons for these findings are not
certain but could be related to a potassium deficit at the renal tubular
site.
Although Apollo 15 was the first mission in which the exchangeable
potassium measurement was made (a decrease), results from other missions
were indicative of similar conclusions.
More specific and definitive explanations of the results on these
two missions are not possible. The return of urine and blood samples
collected during the Skylab flights in 1973 will add the needed data for
interpretation of the environmental changes imposed by space flight.
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TABLE 1-1.- MISSION PARAMETERS OF APOLLO Ik AND APOLLO 15
Parameter
Duration (hr:min)
Landing site
Time on lunar surface (hr:min)
Lunar EVA, number
Lunar EVA time, (hr)
Nonlunar EVA
Postflight quarantine
Apollo lU -
217:03
Fra Mauro Highlands
3U:11
2
9:09
No
Yes
Apollo 15
296:1*5
Hadley Rille
66:55
3
19:09
Yes (38 min)
No
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2. THE MEDICAL ASPECTS OF SPACE FLIGHT SEEN FROM
THE VIEWPOINT OF NUCLEAR MEDICINE
By Philip C. Johnson, M.D., and Theda B. Driscoll
INTRODUCTION
Before Project Mercury, considerable concern and discussion was
evidenced about how the cardiovascular system would respond to prolonged
weightlessness and about how this response would affect the crewmen when
they returned to one-g. Cardiovascular studies were begun in Project"
Mercury and have been continued throughout the Apollo Program. In the
recent Apollo missions, some cardiovascular deconditioning is invariably
present. It is reassuring to note that this decrease generally lasts
only 1 day, but some crewmembers have taken 7 days to return to normal;
however, the crewmembers generally feel well during this time.
Shortly after Project Mercury began, a weight loss of several kilo-
grams was a constant.finding in anyone who returned from orbital flight.
Surprisingly, the first survey publication on this finding did not come .
from the NASA, but rather from a NASA consultant who noted that the
Russian crews had quantitatively similar weight losses. The Russian
results were of particular interest because U.S. space suits, atmosphere,
and small cabin size were eliminated as the cause of the weight loss.
Project Mercury also brought the first attempt at studying the
endocrine changes associated with weightlessness. However, endocrine
studies really began during Gemini VII, the longest mission to date.
Very little attention was given to possible endocrine changes until after
Dr. Leach came to the Manned Spacecraft Center (MSC) and began her com-
prehensive endocrine program. From a humble beginning at MSC, endocrinol-
ogy has increased in stature to a point where I believe it to be a major
thrust of the Apollo medical program.
DISCUSSION
Although endocrine studies had their beginnings in Project Mercury,
radionuclide volume studies did not start until the second manned Gemini
mission. Originally, plasma-volume determinations were initiated to
study the possible relationship between cardiovascular deconditioning
and decreases in blood volume. This study was performed under the first
Atomic Energy Commission license to include U.S. carriers at sea.
2-2
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The first radiopharmaceutical ( I-labelled albumin) was injected
into the two Gemini IV astronauts by personnel at MSC. Baylor College
of Medicine furnished the injection dose, performed the necessary radio-
assays, and did the final calculations to determine the plasma volume of
the two astronauts. A postflight drop in plasma volume was expected
and found. In addition, we found something else which had not been
predicted. This unsuspected finding was that the crewmembers' red. cell
masses had decreased. The red-cell mass was derived from the iodlnated-
human-albumin space and the peripheral hematocrit. While this is not an
accurate way to determine red-cell mass, the findings were sufficiently
great to suggest that a true change had occurred. The decrease in
derived red-cell mass changed the thrust of the radionuclide volume
studies; after Gemini IV, most of our efforts involved investigating the
cause of the red-cell-mass decrease. Dr. Fischer and I believed that
the hyperbaric-oxygen partial pressure in the Gemini atmosphere was the
cause of red-cell-mass decrease, because the Gemini atmosphere was
hyperbaric with .respect to oxygen before launch and in orbit. As the
studies progressed throughout two other Gemini missions, the red-:cell-
mass decrease was quantitated and an attempt was made to explain the
mechanism responsible for the decrease. From the findings and from
other studies, Dr. Fischer came to believe that perioxidation of red-
cell-membrane lipids caused the circulating red cells to die prematurely.
The Apollo Program began with the disastrous fire of Apollo 1.
This fire changed the situation for researchers interested in perioxida-
tion of the red-cell membrane because it resulted in a change in the
atmosphere used at launch. The atmosphere was changed from the Gemini
type, pure oxygen, to one containing 60 percent oxygen and UO percent
nitrogen. Because of the design of the Apollo command module (CM) the
atmosphere is gradually lost after launch. Inflight cabin pressure is
maintained by the addition of pure oxygen. However, the gas-leak rate
is slow enough that residual nitrogen will remain in the atmosphere
unless the hatches are opened for extravehicular activity. Attaching
the lunar module (LM) decreases the. nitrogen partial pressure because
only oxygen is available to compensate for the atmosphere vented into
the LM. Oxygen and nitrogen partial pressures were measured on the
Apollo 7 mission. At the end of the first day, the atmosphere was
80 percent oxygen, and after the second day, the atmosphere was 90 percent
oxygen. The change in the launch atmosphere from 100 percent oxygen to
a UO-percent-nitrogen/60-percent-oxygen atmosphere makes possible a
decrease in the time needed for crew preoxygenation before launch. Even
2
so, breathing 100 percent oxygen at 101080 N/m (?60 torr) for at least
2 hours is still required to prevent dysbarism when the pressure of the
P
CM decreases to 3U3lU N/m (258 torr) upon reaching orbit. Thus, Apollo
crew exposure to oxygen includes 100 percent oxygen at 101080 and
N/m2 (760 and 258 torr).
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The percent of change 'in red-cell mass when the postmission value
is compared with the premission value is presented in table I. The red-
cell mass has generally decreased (19 out of 21 astronauts) during the
orbital missions. After the Gemini missions, the red-cell-mass changes
generally were greater, that is, -8 to -22 percent. On the Apollo mis-
sions, the changes were smaller, but the red-cell-mass decrease was not
caused by blood drawing; blood was drawn from control simultaneously and
the mean values did not change.
The-Apollo missions contrast with the Gemini missions in that the
Cr red-cell survivals are normal for Apollo crewmen. Originally, the
red-cell-mass loss was explained as being a hemolytic event, but as
depicted in the Apollo results, the hyperbaric atmosphere also may be
suppressing red-cell production. Another possibility for the results is
that the high oxygen partial pressures are causing loss of older red
cells. These cells are tagged by the Cr to a lesser extent than are
the younger red cells. Thus, a selective loss of older cells might not
affect the red-cell survival curves of Apollo. The somewhat larger red-
cell-mass drops for Gemini crewmen may have involved more of the younger
cells, thus showing more clearly in the red-cell survivals. The red-
cell-survival results for Apollo missions are shown in table II. The
Cr red-cell-survival results of the missions utilizing the LM (Apollo 9>
iH, and 15) are separated because crewmen showed greater red-cell-mass
losses than did the Apollo missions not using the LM (7 and 8).
Plasma-volume decreases approximately 10 percent with bedrest within
the first 3 or U days, and the plasma volume may decrease as much as
20 percent after prolonged bedrest. The initial 10-percent plasma-
volume loss is caused by the loss of the labile portion of plasma volume.
This portion is helpful in keeping the blood pressure normal as the human
changes from a lying to a sitting position. Bedrest subjects lose this
increment of the plasma volume when they stay recumbent for more than
2U hours. After the first change, a continuing but slower change in
plasma volume occurs. This continuing loss of plasma volume may repre-
sent changes in the body composition caused by inactivity of the muscles
used in standing. Because weight loss does not occur during bedrest,
the muscles would be replaced by fat; fat contains less blood per kilogram
than does muscle.
Urinary excretion of aldosterone is low during bedrest; the decrease
in plasma volume may be one manifestation of this fact. . However, aldo-
sterone excretion has been reported to be elevated during weightlessness.
Elevation of aldosterone should return plasma volume to normal or increase
it to above normal. When arranged according to mission duration, the
results show that the longer the mission, the less the plasma-volume
drop (table III). Red-cell-mass changes were not related to mission
duration; however, blood-volume changes followed the same pattern as the
plasma-volume changes.
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The extracellular-fluid-volume (ECF) measurements made on the
Apollo lU and 15 missions are shown in ta"ble IV. The' 30-minute-
distribution space of S sulphate was determined. Only a slight de-
crease in ECF volume is shown. When this volume is converted to cm /kg
body weight, the ECF values tend to increase postflight. This fact is-
evidence that tissue loss, not ECF loss, was the cause of the body-weight
loss. The results are analogous to what would be expected during star-
vation,.that is, as body tissue is lost, ECF increases to compensate for
this tissue loss. This increase results when muscle mass is lost, de-
creasing the tension on the skin. The decrease in elastic tension of
the skin no longer counteracts vascular hydrostatic pressures. To return
to equilibrium, ECF accumulates and returns the skin tension to normal.
In starvation, the collected fluid is great enough to be seen as edema.
Edema was not found postflight in any of the crewmembers.
Also, the total-body-water results were consistent with a tissue
loss because six out of six values decreased and the changes were gen-
erally greater than the ECF changes (table V). When the total-body
water is corrected to units of cm /kg body weight, postmission increases
are found. Because total-body water included ECF, part of the increase
is from the increased ECF. This fact suggests that the weight loss
included fat (a non-water-containing tissue).
Total-body potassium was determined on the Apollo 15 crewmembers
k2(table VI), The crewmen ingested K and collected a 2^-hour urine. A
spot urine was obtained to determine specific activity. In addition,
the next 2^ -hour urine was collected and another spot urine was obtained
k2 '
to determine specific activity. Although K does not completely equili-
brate within 24 hours, only a slight change was found in specific activity
between 24 and U8 hours, showing that distribution of the ingested radio-
active potassium was nearly complete at 24 hours.
The premission total-body-potassium (K) values were higher than
reported values for normal subjects. However, one astronaut was extremely
well conditioned physically, and all three crewmembers did not have much
fat as was shown by the percent of body water. A significant postmission
drop in total-body K was evidenced in all three crewmembers. After 1 to
2 weeks postmission, total-body K had returned to the premission range.
The postmission total-body-K decrease confirmed the Gemini VII results
and other data, which indicate that aldosterone secretion is elevated
during the mission.
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CONCLUSIONS
The results of the radionuclide volume measurements performed on
the crews who have taken part in selected Apollo missions indicate the
following.
1. Invariably, there Is a small drop in red-cell mass of the
returning crewmembers. This drop is presumed to result from the
hyperbaric-oxygen partial pressures.
2. Plasma-volume decreases similar to those experienced during
bedrest were found in the crewmen of short Gemini missions. After longer
missions, the plasma-volume decrease was no longer present. Increased
aldosterone secretion during weightlessness may account for this differ-
ence between weightlessness and bedrest, the classical experimental
analogue of weightlessness.
3- Extracellular- and total-body water changes prove that space-
flight weight loss includes actual tissue losses. As indicated by the
data, the changes are not only fluid-electrolyte losses.
k. The loss of total-body exchangeable potassium found after the
Apollo 15 mission was evidence of increased aldosterone secretion during •
that mission.
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TABLE 2-1.- RED-CELL-MASS CHANGE ON GEMINI
AND APOLLO MISSIONS8"
Mission
Gemini
VII
V
IV
Apollo
15
9
ll*
7
B
Red-cell-mass change, percent
Astronaut 1
-19
-20
-12
-lit
-1+
-2
-1
+2
Astronaut 2
-a
-22
-!3
-7
-7
-9
0
-2
Astronaut 3
—
—
—
-10
-10
-It
-9
-It
Mean change ,
percent
-lU
-21
-12
-10
-7
-5
-3
-1
Fourteen Apollo control subjects were used; the mean for the
control group was -O.k ± 0.8.
TABLE 2-1I.- 51Cr-LABELLED RED-CELL SURVIVAL DATA&
Experimental
situation
Without LM
Red-cell half
life, days
With LM
Red-cell half
life, days
Specimen-acquisition time
Preflight
25.5 ± 0.8
2U.1 ± 1.1
Inflight
28.3 ± 1.3
25.1 ± 1.3
Postflight
2U.7 ± 1.0
28.2 ± 1.5
Controls = 23.U ± 2.0 days.
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TABLE 2-III.- VOLUME CHANGE IN RELATIONSHIP TO MISSION DURATION
.Mean change
Plasma volume
Red-cell mass
Blood 'volume-
Short ,
50 to 150 hrs
-11 ± 2
-6 ± 3
-9 ± 1
Medium,
150 to 250 hrs
-6 ± 2
-10 ± 3
-8 ± 2
Long,
250 to 350 hrs
+1 ± 3
-8 ± 2
-3 ± 1
TABLE 2-IV.- EXTRACELLULAR FLUID VOLUME
Mission
Astronaut
1 2 3
Mean
Volume change , percent
Apollo Ik
Apollo 15
-0.5
. -U.8
0.0
-3.1
-0.-5'
0.0
-0.3"
-2.6
3
cm /kg change, percent
Apollo lU
Apollo 15
+1.6
-2.0
+9.U
+1.U
+2.5
+1.U
+>*.5
+0.3
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TABLE 2-V.- TOTAL BODY WATER
Mission
Astronaut
1 2 3
Mean
Volume change , percent
Apollo ih
Apollo 15
-1.9
-2.8
-17-7
-3.7
-1.8
-0.8
-7.1
-2.U
3
cm /kg change, percent
, Apollo lU
Apollo 15
+0.h
+0.1
-9.8
+0.6
+1.6
+0.7
-2.6
+0.5
TABLE 2-VI.- APOLLO 15 TOTAL BODY POTASSIUM
Time of sampling
Pref light, meq/kg
Q
ASAP , percent change
R + 6 days , percent change
R + 13 days , percent change
Astronaut
1
5U
-Ik
+k
-2
2
.51
-16
-3
-5
3
9^
-9
-h
+2
Mean
51
-13
-1
-2
As soon as possible after recovery.
R = Recovery.
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3. URINARY EXCRETION OF ANTIDIURETIC HORMONE IN MAN
By Myron Miller, M.D.
INTRODUCTION
For many years, attempts have been made to assess directly neuro-
hypophyseal function in man "by, means of estimation of antidiuretic hor-
mone (ADH) excretion in the urine. Early attempt's vere hindered by the
lack of an efficient, simple procedure for extracting and concentrating
ADH from urine and by the dependence on laborious bioassay procedures for
the quantitation of ADH.
With'the'development of'a sensitive and specific radio'immunoassay
for ADH, along with the application of an efficient extraction procedure .
for ADH, it has been possible to assay the hormone in the urine, thus
providing 'a suitable means for estimation of neurohypophyseal function'. '
In this report, radioimmunoassay has been used to determine1 urinary "ADH
excretion in normal man, to study the.influence of water loading and " '
dehydrati'ori on the excretion of ADH, and to study ADH regulation in sev- '
era! clinical states of abnormal water balance.
The author wishes to express''his appreciation to Mrs. Leelo Bertram
who provided expert technical assistance in performing these studies.
MATERIAL AND METHODS
Twenty-four-hour urine samples were collected in containers to which
2 cubic centimeters of glacial acetic acid had been added. After the
specimen had been collected, the pH was adjusted to U.5 by means of the
addition of further acetic acid whenever necessary. Specimens that were
obtained during water-loading and dehydration tests first were analyzed
for osmolality and then were adjusted to pH U.5 with the addition of
glacial acetic acid. Urine samples that were not further'processed
immediately after collection were stored frozen at 253° K (-20° C).
To extract and concentrate ADH from the urine,'25 cubic centimeter
aliquots of acidified urine were passed 'through columns of the ion ex-
change resin CG-50 and the ADH'was eluted'with 75 percent ethyl alcohol
adjusted to pH 2. The eluates were evaporated'and redissolved in a
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2 cubic centimeter volume and ADH was quantitated using a radioimmuno-
assay procedure. The lower limit of sensitivity of the assay was 25 yU
arginine.vasopressin (AVP)/cm of urine concentrate, thus allowing as
3
little as 2 yU AVP/cm of unextracted urine to be detected.
RESULTS
On lU different occasions, determination of the AVP content of a
standard preparation of beef posterior pituitary extract, as a means of
estimating the reproducibility of the immunoassay procedure, gave a
coefficient of variation of 18.3 percent. Analysis of 32 aliquots of a
single urine specimen, extracted and assayed over a period of 3 months,
gave a similar coefficient of variation of 21.8 percent, indicating that
little additional variability was introduced by the extraction procedure.
When different amounts of AVP were added to urine extracts from a
water-loaded normal subject, the immunoassay curve obtained was identical
to the curve resulting from the original AVP preparations (fig. l).
Thus, no nonspecific effect of the urine extract on the AVP standard
curve was apparent. When varying amounts of AVP were added to 25 cubic
centimeter aliquots of urine from a water-loaded normal subject and then
were extracted and assayed, a linear relationship was found between the
amount of AVP added and the amount of AVP recovered. The percent re-
covery was constant over the range of doses tested (fig. 2).
The CG-50 columns extracted ADH quantitatively when either 25 or
50 cubic centimeter aliquots of urine were applied (table I). .In both
volumes, recovery was complete and similar to the value of 98.5 percent
previously obtained.
• - ,
Acidified urine, frozen for as long as 3 weeks before extraction and
assay, showed no loss of immunoreactivity of ADH (table II). Recovery
of the added AVP was complete. The variability present (l6.8 percent) is
of the same magnitude.as that found in the above determinations of beef
posterior pituitary extract and replicates of a single urine specimen.
In other experiments, frozen samples have been stored for as long as
2 months, and these samples have shown no loss of activity.
In 30 normal male subjects ranging in ages from 12 to U3 years,
urinary ADH excretion under conditions of random diet, fluid intake, and
physical activity ranged from 11.0 to 91.^  mU/2U hr, with a mean value of
28.9 ± 1T.9 (S.D.) mU/2H hr or 1.20. ± 0.75 mU/2U hr (table III,.fig. 3).
The distribution of values is skewed so that the median value is
22.8 mU/2U hr and 70 percent of the subjects excreted less than 30 mU
ADH/2i| hr and only 13 percent excreted more than 50 mU/2U hr (fig. 3).
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In ..five subjects, urine was collected from time of arising to time
of bed and- from'time of bed to. time of arising (table IV).' Mean urinary
ADH excretion during the daytime hours was 0.92 ± 0.20 (S.E.) rnU/hr and
during sleep-was 0.68 ± 0.13 mU/hr. These values were not significantly
different from each other... Mean urinary ADH excretion during sleep in
12 :.subjects was 0.96 ± 0.20 mU/hr, a value not different significantly
from the value of-1.20 ±: O.lU mU/hr for .the hourly excretion over-the
total 2k hours in the. 30 normal subjects.
Water loading was performed by administering orally 20 cubic centi-
meters of water per kilogram of body weight and then replacing voided
urine, volumes with "an equal volume of tapwater to maintain "the water load.
Voided urine specimens were -collected at 15-minute intervals during the
period of diuresis and analyzed for volume, osmolality, and ADH. The :.~
response in a normal subject is shown in figure 1*. Following ingestion
of the water'load and the beginning of diuresis, urine osmolality fell
from 925 to TO mOsm/kg. In parallel• with the fall in urine' osmolality-,
urinary ADH excretion fell rapidly from 2.6 mU/hr to levels'that-were
undetectable and remained at those levels during the period 'of' diuresis-.•=
When water was withheld so that the urine- osmolality began to- rise, again
ADH'appeared'in the urine, first being apparent when the urine osmolality
reached-'86 mOsm/k'g. '-" . - ' •• • •'• • •• - -'- •
Following'- the'- administration of a maintained oral-water load to •
22 normal subjects, plasma osmolality/fell from 281* to 293'm6sm/kg to '''••'
269 to 283 mOsm/kg with concomitant onset of diuresis of 600 to
11*80,-cm /rhr.and -decrease in urine osmolality to- U5 to 86 mOsm/kg. During
the .peak.of the diuresis,;. ADH ^excretion was not detectable,-in 19.. of the .
22
 ;subject,s (fig. 5)..- ..: . . - '- " ., ' - . . . .
..The response to 17 hours of fluid deprivation in a normal' subject
is shown in figure 6. By the twelfth to fifteenth hour of fluid .depriva-
tion, urine osmolality reached a maximum value of 1090 mOsm/kg and did
not increase further with an additional 2 hours of .dehydration. Urinary
ADH excretion rose progressively from O.U2 mU/hr in the predehydration
period to a maximum of 1.98 mU/hr by the sixteenth hour of fluid
deprivation.
.. Urine, was collected .from.the hours 13. to 1^4 after fluid deprivation,
in 13 normal subjects. Urinary ADH excretion increased in each subject,
from 1.00 ± 0.19 mU/hr in the predehydration period to 2.?U ± 0.53. mU/hr
after lh hours of dehydration, (fig. T)- During the same, time intervals,
urine osmolality rose from 9^1 ± ^ 8 to 1000 ± ^7 mOsm/kg. Mean plasma
osmolality at the end of the dehydration period was 290.6 ±.1.0 mOsm/kg.
Studies were conducted on six patients who had severe hypothalamic
diabetes insipidus, with urine volumes that ranged from 1*700 to
10 700 cm /2U hr. With the patients on ad libitum fluid intake, urine
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osmolality ranged from 80 to 197 mOsm/kg. Plasma osmolality ranged from
292 to 300 mOsm/kg, and no ADH was detectable in the urine (fig. 8).
Three patients with congenital nephrogenic diabetes insipidus were
studied. In contrast to the patients with hypothalamic diabetes insipidus,
these patients on ad libitum fluid intake had urinary ADH excretion rang-
ing from 1.15 to ^ .30 mU/hr. After 5 hours of water deprivation, urinary
ADH excretion rose significantly to U.83 mU/hr in one subject and to
27.52 mU/hr in another subject'. When the patients were given an oral
3
water load of 20 cm /kg body weight, urinary ADH became undetectable
(fig. 9). Therefore, patients with nephrogenic diabetes insipidus excrete
large amounts of ADH under conditions of both random hydration and fluid
deprivation.
Six patients with inappropriate ADH syndrome were studied, five of
whom had oat cell carcinoma of the lung. Urine osmolality ranged from
^50 to 960 mOsm/kg during ad libitum fluid intake. Only one of these
patients, who excreted 13.2 mU/hr, had urinary ADH excretion in excess of
that found in normal individuals (fig. 10). However, when the urinary
ADH excretion was related to plasma osmolality, it was apparent that the
ADH excretion was inappropriate (fig. ll). In normal subjects, ADH ex- .
cretion generally is undetectable when the plasma osmolality is less than
28l mOsm/kg. In the patients in whom plasma osmolality ranged from
25^ to 270 mOsm/kg, urinary ADH was always present.
The patients were given an oral water load, which further lowered
plasma osmolality to a mean of 251 mOsm/kg, and the response was con-
trasted with the response seen in normal subjects (fig. 12). Urinary •••
ADH excretion fell but was never undetectable, in contrast to what was
seen in normal subjects where ADH could not be found in 19 of 22 subjects.
Urine volume did not increase and urine osmolality fell only modestly
from 667 to 522 mOsm/kg.
CONCLUSIONS
The studies shown here indicate that urinary excretion of ADH can be
detected readily and quantitated accurately. The ADH excretion in normal
subjects is seen to be inhibited following the administration of a water
load and to be stimulated following water deprivation. It appears that
measurement of ADH excretion in man can provide a means of quantitating
alterations in neurohypophyseal ADH secretion. By determining not only
the basal excretion of ADH but also the response to such physiological
influences as water loading and dehydration, it becomes possible to study
the dynamics of ADH release. Thus, the ability to extract ADH efficiently
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from urine combined with a sensitive and specific technique for determi-
nation of ADH concentration allows the exploration of regulatory systems
for ADH control in the normal state-.as" well as the etiological role of
altered ADH secretion in clinical disorders of water balance.
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TABLE 3-1.- RECOVERY OF ARGININE VASOPRESSIN FROM
25 AND 50 CUBIC CENTIMETER ALIQUOTS OF URINE
25 cubic centimeter aliquot,
0.33 mU/25.cm3
mU/25 cm3
0.38
• -.--su • ;
.39
.36
.37 .
'.3U '
.ho
.28
.37
•3.6
0.36
Percent recovery
115
103
118
109
112
103
121
8U
112
109
50 cubic centimeter aliquot,
0.66 mU/50 cm3
mU/50 cm3
0.68
.7U
.69
• 7U
.70
.52
.70
.60
.58
.48
Percent recovery
103
112 ~':'~
10 k
' 112 •••"" ' •
106
'78
106
91
88'
72
Mean
109 0.6U 97
Standard error of the mean
0.01 3.3 0.03 U.5
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TABLE 3-H.- RECOVERY OF ARGININE-VASOPRESSIN ADDED
'TO URINE'AND FROZEN'FOR UP TO 22 DAYS
BEFORE EXTRACTION AND ASSAY
T> •£*Days irozen
1
8
lit
22
AVP, 0.33
o
mU/25 -cnr
0.38
.. .31* ,
'.39 '
.36
. .37
••- .32 ,
.31
a
.35 ± 0.01
o . 31* •
.1*0
.28
.37 .
• 36 ;
.25
.27
a
.32 ± 0.02 .
''.' 0.21+
.25
0.1*2
.39 /
. . . "3 .
mU/25 cm
Percent recovery
115
: 103
118 • '.
109
112
97 >
91*
•
 a!07 ± 3.1*
• , 103 '
121 .
: si*
112
; 109
76 '
82 •
\ a98.± 6.6
: 73 .
76
 • ;
• 127-
118 .-
"Mean ± standard error of the mean.
Mean.
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TABLE.3-III.- TWENTY-FOUR HOUR URINARY ANTIDIURETIC HORMONE DATA
[Thirty normal male subjects, ranging in age from 12 to 1*3 years]
Subject
J. L.
D. M.
R. B.
R. C.
A. P.
M. M.
J. C.
J. G.
R. Co.
K. T.
D. H.
A..S.
'P. H.
J. V.
D. L. .
D. C.
M. Mi.
D. Ha.
A. M.
R. Cou.
P. Ho.
N. E.
M. B.
R. F.
K. Tu.
J. Cr.
A. K.
T. W.
M. W.
J. W.
Age,
yr
1*3
23
27
26
2k
36
12
26
27
26
25
26
25
26 .
23
22
37
26 .
1*1
28
26
23
21*
23
25
26
25
25
2k
28
ADH excretion,
mU/2l* hr
11.0
11.6
12.5
13.3
13.3
ll*.7
15.9 '
16.5
16. 6
17.1
17.6
18.8
20.2
21.9
22.8
25.6
25.6
26.3
27.6
28.5
29.6
31*. 7
39.6
Ui.i
1*1*. 9
U9.6
51.1
52.5
56.2
91. U
Urine volume,
cm3/2U hr
1000
700
820
950
lOiO
800
620
1020
20l»0
281*0
1000
2180
720
ll*l*0
1190
955
780'
3130
1150
990
1*75
985
990
870
1220
1070
760
925
990
1360
Urine osmolality,
mOsm/kg
1036
755
995
10l*U
756
893
1120
850
• 1.56
U67
958
577
1098
915
881* •
101*0
935
377
988
101*1
1226
862
.1062
1026
819
8llt
1131
99U
978
988
Creatinine excretion ,
g/2l» hr
1.8
.
2.0
1.6
1.3
l.U
• —
~
2.1 -
!-3 .
1.9
2.2
1.7
2.6
2.1
1.8
2.3
2.0
1.8
1.1*
2.0
—
1.3
2.3
1.8
1.7
1.9
2.0
2.0
Mean
—
—
28.9 I 1167 903 1.9
Standard deviation
~
—
17.9 | 610 206 0.3
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TABLE 3-IV.- ANTIDIURETIC HORMONE
EXCRETION DURING WAKING HOURS AND
DURING SLEEP IN NORMAL SUBJECTS
Subject
1
2
3
It
5
ADH excretion, mU/hr
Awake
1.59
.35
.99
•71
.95
Asleep
O.i tU
.78
l.lU
.62
.1*2
Mean ± standard error of the mean
—
0.92 ± 0.20 a0.68 ± 0.13
= Not significant compared to awake.
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AVP,
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Figure 3-1.- Standard curve prepared in the usual fashion (solid dots)
compared with standard curve prepared by adding AVP to dried extract
of urine from a water-loaded normal subject (open triangles). The two
curves are identical, indicating the absence of a nonspecific effect
of the urine extract on the curve.
1400
1200
1000
800
600
400
200
Slope- 1.21
R-0.995
200 400 600
AVP added.
 fU
800 1000
Figure 3-2.- Recovery of varying amounts of AVP added to 25 milliliters of
urine aliquots obtained from a water-loaded normal subject. The amount
of AVP added is plotted on the X axis while the amount of AVP recovered
is plotted on the Y axis.
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Figure .3-3.- -Urinary excretion .of ADH in--2Who\ir .urine, collec,t,ions.i.r!frpm
30-normal'male subjects, expressed as.mU/Sk.hr on the- left,-,and.-,.as mU/hr
on the right. Seventy percent of the values are less than 30 m\J/2k hr.
20 cm'flq miintitnitf
c[»
5
 0
; ion
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Figure 3-^ .- Response to a maintained oral-water load of 20 mg/kg in a nor-
mal subject. 'After maximum diuresis was achieved, further water inges-
tion-was discontinued and the subject was allowed to excrete the water
load. No ADH was detectable in urine collected from hours: 3" tb'i-5." • .
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Figure 3-5-- Response to maintained oral-water load of 20 ml/kg in 22 nor-
mal subjects. Values Just before the water load and during the period
of maximum diuresis for each of the parameters measured are plotted
for each subject. Mean values are indicated by the horizontal lines.
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Figure 3-6.- Response to 17 hours of fluid deprivation in a normal subject,
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Figure 3-7-- Urinary ADH excretion following lit hours of fluid deprivation
in 13 normal subjects. Values just before fluid deprivation and dur-
ing the hours 13.and 1^  of fluid deprivation are plotted for each sub-
ject. Mean values are indicated by the horizontal lines. In response
to fluid deprivation, urinary ADH excretion increased in each subject.
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Figure 3-8.- Urinary ADH excretion and osmolality.in 2U hour,urine .collec-
tions- from six patients vith severe hypothalamic diabetes, insipidus" ?
Csolid dots). The normal range for ADH excretion and urine .osmoisilty
is indicated by the shaded area.
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Figure 3-9.- Urinary ADH excretion in three patients with nephrogenic dia-
betes insipidus under conditions of ad libitum fluid intake and after
dehydration and water loading.
13.5
13.0
3.0
\I
§ 2 . 0
i.o
200
I Norm* range
400 600 800
Urine oynddity, mOun/kg
1000 1200
Figure 3-10.- Urinary ADH excretion and osmoiality in 2U-hour urine collec-
tions from six patients with the inappropriate ADH syndrome.(solid
dots). The normal range is indicated by the shaded area.
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Figure 3-11.- Correlation of urinary ADH excretion with plasma osmolality
in normal subjects during various states of hydration and in patients
with the inappropriate ADH syndrome.
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Figure 3-12.- Response of urinary ADH excretion, volume, and osmolality
to oral water loading. The response in patients with the inappropri-
ate ADH syndrome (right) is compared with that in normal subjects
(shaded area on the left).
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U. ESTIMATION OF VASOPRESSIN EXCRETION IN THE URINE AS A METHOD OF
MONITORING VASOPRESSIN SECRETION DURING SPACE FLIGHT
By Walter H. Moran, Jr., M.D.
INTRODUCTION
The monitoring of the urinary excretion of antidiuretic hormone
(ADH, arginine vasopressin) as a measure of ADH neurosecretory activity
during space flight might "be considered to be a step backward or, at
best, a temporary expedient until better methods for the estimation of
plasma ADH levels are available. In the discussion that follows,.it will
be demonstrated that, under the circumstances of space flight, the meas-
urement of plasma ADH levels might be misleading and that only the uri-
nary ADH levels would provide reliable information. The results of a
partially completed survey of ADH levels in urine samples from human
subjects in which simultaneous plasma ADH levels were available also are
included.
DISCUSSION
The monitoring of urinary ADH levels during space flight was not
considered seriously until 1969, when a change in plans was caused by
technical necessity rather than by theoretical considerations. Until .
that time, considerable effort had been spent in developing and testing
techniques for the preservation of ADH in plasma samples during long
space flights. To determine the magnitude of the ADH levels that might
be encountered, plasma samples were obtained from the Apollo 9 crewmen
before lift-off and at various intervals after recovery. These determi-
nations were unsatisfactory technically because the volume of plasma re-
maining after aliquots for other important tests had been removed was
insufficient for the number of replicates required for the biological
assay used to determine significant changes at the ADH levels encountered.
A second factor making the determinations technically unsatisfactory was
the presence of a substance that produced an osmotic diuresis of short
duration in the rats used for the bioassay and made a quantitative inter-
pretation of th.e antidiuretic responses difficult. Furthermore, the
range of plasma ADH levels encountered fell along that portion of the
biological dose-response curve where very small changes in ADH levels are
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associated with large changes in urine flov, making it doubtful that
even an immunoassay requiring only 1 cubic centimeter of plasma would
be sufficiently precise without at least four or five replicates.
Because of considerations, the use of plasma samples was abandoned
and attention was focused on sampling urine.
The use of such indirect parameters as the classical change in
"free-water clearance" (CHOH) was considered briefly because of the pos-
sibility of inflight measurement by electronic means. Before adequate
assays for vasopressin were available, changes in CHOH frequently were
used to monitor ADH secretion. At that time, investigators fully
understood that the results obtained were valid only if the subject were
artifically maintained in a state of diuresis; in other words, the
urinary solute concentration was less than or equal to that of the plasma
solute concentration. Investigators also recognized that a maximum
urinary concentration existed that could not be exceeded, no matter how
much ADH was administered. The osmolal clearance associated with this
maximum urinary concentration was called the "osmotic floor" of urine
excretion. Because urine is almost always hypertonic in normal indi-
viduals and might be expected to be hypertonic during some periods of
space flight, the concept of monitoring 'CHOH was not considered further.
The only remaining possibility was to monitor the urinary excretion
of ADH.
The estimation of urinary ADH levels was used extensively during
the 1950's, before satisfactory plasma methods had been developed.
However, investigators were skeptical of the values obtained by the
estimation. Because only 10 percent of injected ADH appeared in the
urine, investigators felt that the urinary ADH levels would be very
susceptible to changes in rates of hepatic detoxification and renal
clearance and might not accurately mirror changes in ADH secretion.
These criticisms are valid and must be kept in mind when interpreting
urinary ADH levels, but, as will be mentioned later, these same criti-
cisms also apply equally well to plasma ADH levels.
By the early 1960's, adequate methods had been developed to allow
measurement of ADH in reasonably large samples of human plasma. In
these methods, an initial step of concentration and desalting on an
ion-exchange resin was followed by an intravenous antidiuretic bioassay
in a rat. Within the next few years, a great deal of information was
gained using this type of assay; however, no new receptors or control
systems were discovered as a result of these studies. Most of the new
information concerned the quantitative aspects of ADH secretion, which
had been greatly underestimated when the renal tubule was the only
indicator. This new information led to new concepts concerning the
methods by which the ADH control systems integrate their functions.
U-3
The first important concept to emerge was that of a hierarchy of
closed-loop control systems "based on the biological effectiveness of ADH
on the target organ affecting the controlling sensor. It was found that
purely osmotic stimuli could modulate blood ADH levels over a range from
0 to 6 yU/cm . This range also corresponded to the range in which the
renal tubule could respond to blood ADH levels (by reducing urinary out-
put) by conserving water alone. The response was exponential, with the
largest changes in urinary volume occurring in conjunction with the smallest
changes in plasma ADH levels at the lower limits of plasma concentration.
As plasma levels rose and approached the tubular limit, larger and larger
changes produced smaller and smaller changes in urinary volume until the
"osmotic floor" was reached. This reaction implied that the osmoreceptor
control system is a closed-loop feedback system that depends on the bio-
logical effectiveness of ADH on the renal tubule to close the loop. The
stiffest point of control was about the point where urine was isotonic
with plasma and at a point where plasma ADH levels were the most difficult
to determine. If the renal tubules could not respond to ADH, as in the
case of nephrogenic diabetes insipidus, ADH secretion was not inhibited
and control passed to the next system in the hierarchy, the left-atrial
low-pressure volume-control system. This system can modulate blood ADH
2
levels from 0 to 60 uU/cm and, therefore, can control renal tubular water
reabsorption as well as control the stretch of the left atrium by means
of rerouting the visceral blood flow. The third closed-loop control sys-
tem of the hierarchy consists of the baroreceptor system, which can modu-
o
late ADH blood levels over a range of 0 to 600 yU/cm or greater and which
feeds back through the vasoconstrictor effect of ADH on large vessel
walls. Unfortunately, urinary ADH levels were not checked during these
investigations, so it is impossible to tell if urinary ADH excretion ap-
proached a limit as visceral blood flow was altered. Usually, the urinary
output was very low during these periods.
The second concept to emerge from studies involving the use of
plasma ADH levels to monitor ADH secretion was the discovery of the
extremely transient nature of blood-level elevations and the speed of
the neurosecretory response or release to stimuli. The maximum ADH blood
level obtainable from a single 1-minute step input had occurred before
the stimulus was completed. The biological half life of ADH in the blood
stream was approximately 3 minutes, indicating that sampling at least
once per minute would be required in order to adequately monitor a
secretory-response pattern. The effect of changes in the rates of
hepatic detoxification, the volume of distribution caused by changes
in the state of hydration, and the changes in renal clearance could have
a significant effect on plasma ADH without necessarily mirroring changes
in ADH release from the neufohypophysis. A significant rise in the
plasma ADH of a crewman during the entry of a space vehicle might be
dissipated before a blood sample could be drawn, but the increased amount
of ADH cleared by the kidney would still be in the urinary bladder.
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The last point in the previous paragraph is illustrative of one of
the most important advantages of measuring urinary ADH levels, that of
cumulative integration. The best example of the usefulness of this
technique as far as vasopressin is concerned occurred in 1953, when
Ames (ref. l) reported that she had observed extremely high levels of
ADH in the urine of infants shortly after birth but vas unable to dete,ct
any ADH thereafter until the third or fourth month of life. Because
these results had been obtained from urinary determinations and could
not be reconciled logically vith any current point of,.view, the high
urinary ADH levels after birth generally were disregarded. This point
of view was reaffirmed further when early attempts to measure plasma
ADH levels in infants revealed that ADH could not be detected in the
plasma until the third or fourth month of life (ref. 2). However, when
more sensitive methods for measuring plasma ADH levels were applied, the
transitory increase at birth of the ADH secretion, which had been inte-
grated in the urine, was confirmed (ref. 3).
Another advantage of monitoring urinary ADH levels is that the
concentration of ADH in the urine is at least 1000 times that found in
plasma, allowing for precise determinations in small aliquots using
currently available immunoassay techniques, such as the one described
by Dr. Myron Miller in the previous paper. Finally, none of the in-
formation gained by using urinary ADH determinations has been subsequent-
ly disproven by use of the plasma ADH assay.
The principal problems to be faced in applying the urinary ADH
assay are the degradation of ADH in the bladder before excretion, the
presence of interfering substances, and the effect of reduced renal
clearance on the excretory limit of ADH.
RESULTS
Since 1962, aliquots of urine from patients undergoing studies of
their plasma ADH levels have been collected, frozen, and stored. Re-
cently, a program of determining the ADH content of the samples was
undertaken to ascertain the range of urinary ADH levels that might be
encountered in pathological conditions and to see if any relationship
exists between urinary ADH excretion and plasma ADH levels. There were
no normal subjects in this group.
The urinary assay of ADH consisted of a modification of the plasma
ADH bioassay procedure. The urine samples, which had been frozen without
the addition of any preservatives, were thawed rapidly and extracted
with 2 volumes of ether. Then, the washed urine was adjusted to a pH of
^.2 and was added to a column of CG-50 resin. From this point on, the
procedure was identical to the plasma bioassay. The extracts of urine
produced antidiuretic responses that were similar to those produced by
the arginine vasopressin reference standards. The high levels in some
of these samples were indicative that very little (if any) ADH had been
lost during prolonged storage. At present, 90 urine samples have been
assayed, 57 of which had plasma ADH levels timed so that ADH clearances
could be calculated.
Five patients might be classified as having diabetes insipidus (Dl)
(table l). The DI-1 and DI-2, patients had pulmonary carcinoma and
metastases to the brain. The DI-3 patient had a carcinoma of the thyroid
and cerebral metastases as a cause of her DI. The Dl-k patient was a
boy with DI, and DI-5 was a diabetic who had severe retinopathy and was
undergoing a pituitary-stalk section. The urinary ADH levels were very
O
low in this group, ranging from not detectable to 9.4 yU/cm . Plasma
samples were taken infrequently because of the difficulty in detecting
ADH levels in DI patients. The high plasma ADH level in DI-2 occurred
after a dose of vasopressin, and the high plasma levels in DI-5 occurred
during the surgical procedure. The mean urinary ADH excretion rate in
DI without an open loop stimulus was 9-93 ± 0.1 yU/min (N = 12). The
mean urinary ADH excretion, when injected pitressin had achieved a clin-
ically satisfactory response (DI-2), was 11.6 ± 0.9 yU/min (N = 7).
Two surgical patients (SURG-1 and SURG-2) had samples taken while
they were undergoing surgical procedures (table II). A partial gastrec-
tomy was performed on SURG-1; a partial colectomy was performed on
SURG-2. Their mean urinary ADH excretions were 339 ± 58 (N = 6) and
2Ul ± 29 (N = 6) yU/min, respectively.
Four patients had the inappropriate antidiuretic hormone secretory
(lADHS) syndrome (table III). The cause of the inappropriately high
ADH levels in IADHS-1 was severe pulmonary emphysema. Although his
urinary excretion rate (8.6 ± 3 yU/min (N = U)) and plasma levels
Q
(2.6 ± Q.k yU/cm (N = k)) might be considered to be within the normal
range, they were definitely too high for his plasma osmolality of
2^0 mOsm/yg and were unresponsive to water loading. The IADHS-2, IASHA-3,
and IADHS-U patients had oat-cell pulmonary carcinomas. Their urinary
ADH excretion rates were quite high (Ull, 50.1, and 22U yU/min) and
were unresponsive to water loading.
The average values for urinary ADH excretion, plasma ADH concentra-
tion, and renal clearance of ADH are listed in table IV. The ADH clear-
ance data of the DI patients were insufficient to warrant any conclusion.
The ADH clearance values of all of the patients except IADHS-2 varied
between 3.7 and'11.5 cm /min but were not really significantly different.
The U3.5-cm /min clearance of IADHS-2 cannot be explained at present.
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Careful examination of the data in tables I, II, and III revealed
that small changes in urinary flow in patients with low urinary outputs
were associated with small changes in urinary ADH excretion that were
directly proportional and were probably related to small changes in
renal clearance. If the urinary output was high and not completely
osmotic, the urinary flow was inversely proportional to ADH excretion -
(DI-2 and DI-5).
A plot of all 57 urinary ADH excretion rate/plasma ADH concentration
value pairs (fig. l) demonstrated a fairly linear relationship between
them. Five of the points from SURG-1 fell far above the line and rep-
resented a period when both renal and hepatic clearance could have
been reduced.because of events surrounding the surgical procedure. The
other point for this patient .fell on the plotted line and represented
the highest urinary ADH excretion rate observed (6l6 uU/min). The
points from IADHS-2 fell below this line, as was mentioned earlier. In
general, the urinary ADH excretion rates paralleled plasma ADH concen-
trations, giving an average renal clearance of ADH of approximately
3
10 cm /min.
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TABLE U-I.- DIABETES INSIPIDUS
Patient
DI-1
DI-2
DI-3
DI-U
DI-5
Urine tests
Duration ,
min
of test
720
720
60
60
60
• 60
60
60
60
60
60
15
15
15
15
15
15
15
15
60
60
60
60
60
60
60
2Uo
120
120
120
360
360
Rate\
cm /min
V
0.6?
1.39
18.92
10.83
6.33
U.25
3.00
2.67
2.33
1.65
• 93
1.53
1.UO
2.67
14.33
14.80
14.80
5.140
U.67
1.50
1.80
1.08
.50
.83
1.25
1.00
• 73
.82
• 53
• 53
• 90
3.32
ADH,
yU/cm3
U
l.U
1.2
.6
.3
1.1
3.3
U.6
U.O
5.5
7.3
.6
.3
.3
N.D.°
N.D.
N.D.
N.D.
N.D.
N.D.
l.U
.3
.7
l.U
1.2
.9
.8
1.9
9.U
7.5
3.8
5.3
.8
ADH,
yU/min
UV
1.0
1.6
11.0
3.2
7.1
1U.2
13.6
10.6
12.8
12.0
.6
.5
.3
—
2.1
.6
.8
.7
1.0
1.1
.8
l.U
7.7
U.o
' 2.0
U.8
2.8
Plasma
tests
ADH,
yU/min
P
0.0
—
6.3
—
—
—
— _
.7
•
—
—
—
_^
—
—
—
—
—
—
12.8
6.8
—3.1
2.7
—
Renal clearance
rate, ADH
cm /min
.UV/P
__
—
0.5
•_ —
__
__
__
„
_^
.5
_ ^
• -•• __. • -. ...v
— _ '
__
__ •.
: • — •
—
 ^
. .
_— -
—
.-.-'.
.1.
'1.1
. —
.7
1.8
—
length of time of pool or interval of sampling.
Amount of urine excreted in 720 minutes.
CN.D. = Not detectable.
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TABLE U-II.- SURGICAL PROCEDURE
Patient
Surg-1
Surg-2
Urine tests
Cl
Duration ,
min
30
30
30
30
30
30
30
30
30
30
30
30
30
Rateb,
cm /min
V
1.30
2.U7
U.17
1.90
1.83
1.30
1.83
5-03
8.63
7.83
6.23
--
1.12
ADH,
yU/cm3
U
VTU.
118.
81.3
117.
135.
2U3.
1U9.
59.0
29.1
29.2
U7.0
—
96.9
ADH,
yU/min
uv
6l6.
291.
339.
222.
2U8.
315.
273.
297.
251.
229.
293.
—
108.
Plasma
tests
ADH,
yU/cm3
P
hi. 2
U U . 2
Ul.O
5U.2
5U.5
U5.7
21.8
2^.7
17.5
23.7
20.8
—
16.7
Renal clearance
rate , ADH
cm /min
UV/P
15.0
6.6
8.3
lt.1
U . 5
6.9
12.5
12.0
1U.U
9.7
lU.i
—
6.5
l,ength of time of pool or interval of sampling.
Amount of urine excreted in 720 minutes.
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TABLE lt-III.- INAPPROPRIATE ADH SECRETORY SYNDROME
Patient
IADHS-1
IADHS-2
IADHS-3
Urine tests
Q
Duration ,
min
ll*l*0
ll*l*0
ll*l*0
ll*l*0
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
Rateb ,
cm /min
V
0.1*1*
.29
.3l»
.10
.93
.85
1.21
1.1*6
1.85
1.95
1.31
1.33
.95
.93
.57
1.0U
.71*
1.00
.61
.88
.73
1.18
.1*6
1.15
.57
ADH,
pU/cm3
U
17.5
1*8.9
33.3
12.5
359.
3UO.
1*1*5.
3M.
283.
2U5.
339.
3l*2.
295.
307.
73.5
58.1*
71.0
1*5.1*
70.2
1*6.7
63.6
1*1*. 5
56.lt
51*. 6
58.1*
ADH,
yU/min
UV
7.6
ll*.3
11.3
1.3
331*.
288.
537.
1*97.
522.
1*75.
1*1*2.
1*55.
278.
285.
1*1.8
60.1*
52.3
1*5.1*
1*2.9
1*1.2
1*6.1*
. 52.5
25.8
62.9
33.2
Plasma
tests
ADH,
uU/cm3
P
1.5
2.1*
3.6
2.7
11.7
9.7
9.1
13.8
8.5
—
9.9
—
6.3
—
1*.7
5.8
5.5
6.5
5.9
l*.2
5.0
5-9
fc.7
5.1
6.3
Renal clearance
rate, ADH
cm /min
UV/P
5.0
6.0 .
3.2
9-5
28.5
29.7
58.9
36.1
61.8
—
»tU. 7
—
1*1*. 8
~
8.9 ;
10.5
9.6
7.0
7.3
9.8
9.3
8.9
5-5
12.3
5.3
of time of pool or interval of sampling.
Amount of urine excreted in 720 minutes.
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TABLE U-III.- INAPPROPRIATE ADH SECRETORY SYNDROME - Concluded
Patient
IADHS-3
IADHS-U
Urine tests
fl.
Duration ,
min
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
720
Rate13,
cm /min
V
1.13
1.29
1.25
2.08
1.U6
.82
.96
.1*6
.51*
.80
1.29
1.0U
1.53
2.614
3.11
.78
1.10
.61
.83
.60
.78
ADH,
pU/cm
U
1*7.7
39.7
1*3.6
30.3
51.0
68.6
6U.3
10U.
61*. 3
230.
177.
181.
171*.
125.
116.
231.
226.
198.
257.
21*1*.
283.
ADH,
pU/min
UV
53.6
51.2
5H.1*
63.0
7l*.l*
56.2
61.6
1*7.6
31*. 8
18U.
228.
189.
265.
329.
361.
180.
2U8.
119.
211*.
11*6.
220.
Plasma
tests
ADH,
•pU/cm3
P
5-3
6.9
8.7
8.3
9.7
6.5
6.5
7.0
—
13.7
16.1
20.1
17.3
18.7
—
21.0 •
—
21.1
—
21.2
—
Renal clearance
rate, ADH
cm /min
UV/P
10.2
7.U
6.3'
7.6
7.7
8.7
9.5
6.8
—
13.1*
lU.2
9.1*
15. U
17.7
—
8.6
—
5.7
—
6.9
—
Length of time of pool or interval of sampling.
Amount of urine excreted in 720 minutes.
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TABLE U-IV.- AVERAGES FROM TABLES I, II, AND"III
Patient
DI-1
DI-2
DI-3
DI-U
DI-5
SURG-1
SURG-2
IADHS-1
IADHS-2
IADHS-3
' lADHS-it
Urine ADH,
yU/min
UV
1.3 + 0.3(N=2)
12.6 + .63(N=5)
.5 + .1(N=3)
1.0 + .2(N=7)
3.8 + .9(N=6)
339. + 58(N=6)
2Ul. + 29(N=6)
8.6 +_3.(N=1»)
Jtll. + 33(N=10)
50.1 + 2.6(N=20)
22k. + 20(N=12)
Plasma ADH,
MU/cm3
P
0.0
6.3
O.T
—
6.U + 2.(N=U)
U6.8 + 2.5(N=6)
20.9 + 1.3(W=6)
2.6 + O.U(N^U)
9.9 + .9(N=7)
6.2 + .3(N=19)
18.7 + .97(N=8)
Renal clearance rate,
0
cm /min
UV/P ,. ....
— . '.-'."
0.5:
 ;
:;
0.5^ rv
— •
0.9 + 0.6(N=U)
7.6 + i.6(N=6)
11.5 + ,l.2(N=6)
3.7 +,i.2(N=ti)
3^.5 + 5.0(N=7)
Q.h + O.It(N=19)
11.^  +. 1.5(N=8)
k-12
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Figure i*-l.- A plot of the 57 urinary ADH excretion rate/plasma ADH con-
centration pairs. The cluster of five points between 200 to 350 yU/min
and above ^0 yU/ml represents SURG-1. The cluster of seven points be-
tween 250 to 550 yU/min and below 15 uU/ml represents IADHS-2.
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5. ADRENOCORTICOTROPHIC HORMONE LEVELS
IN GROUND BASED STUDIES
By Bonnalie 0. Campbell, Ph. D.
INTRODUCTION
Beginning with Project Mercury, the function of the adrenal gland
has .been considered an important, factor in the adaptation of man to
space flight. A study of the pituitary-adrenal axis has offered the
potential of assessing human metabolic response to the possible mental/
physical stresses of prolonged space flight.
An investigation of the role of adrenocorticotrophic hormone (ACTH)
in the pituitary-adrenal axis has established normal circulating values
for this hormone in both plasma and serum samples. Levels of ACTH have
been determined for a series of ground-based studies of imposed vork/rest
cycles.
METHODS
Immunoreactive ACTH was measured directly using human venous -plasma
and serum. Duplicate samples of standards (Lerner human ACTH) and plasma-
EDTA or serum were extracted and assayed using the method described by
Donald (ref. l). Rabbit antihuman serum was used at final dilutions of
1251:20 000 and 1:30 000. The labeled ^1 human ACTH was repurified each
time before use. The total incubation time was U to 5 days at 277° K
(h° C). A dextran-coated charcoal preparation was used for separation.
Both supernatant and charcoal fractions were counted for 10 minutes.
Calculations were based on precent binding compared with B/F ratios
(fig. 1).
DISCUSSION
To establish normal baseline levels of ACTH secretion for healthy
human adults, only blood samples collected under similar conditions were
analyzed. Blood was drawn during the morning and afternoon hours under
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conditions normally not considered conducive to stress. A study of cir-
culating plasma levels of ACTH in 105 healthy employed adults is summa-
rized in table I. The mean level of plasma ACTH for all subjects was
3 323.1 pg/cm . The mean value of ACTH was 25-0 pg/cm for 76 males ranging
in ages from 2U to 6l years. The mean value for 29 females, ranging in
2
ages from l6 to k5 years, was 18.1 pg ACTH/cm . When the data were sep-
arated into morning and afternoon values, there was an apparent elevation
of levels of ACTH secretion in the afternoon for both sexes and higher
values during both periods were recorded for males (table II).
When the data were separated on the basis of sex, the level differ-
ence was shown to be nonexistent when the samples that were collected
under identical conditions and that were closely related in time were
analyzed (table III). Seventy-five employed individuals of both sexes
were tested in a routine situation (an annual physical examination). The
samples were obtained between 07^ 5 and 0855 and all samples were obtained
by the same trained laboratory personnel. The mean level of plasma ACTH
for 62 males was 20.7** pg/cm . The mean level of the hormone for
13 females was 20. U6 pg/cm (ref. 2).
A study was initiated to investigate the feasibility of the use of
serum in addition to plasma-EDTA. The values for human serum were ob-
tained under essentially the same conditions as for those cited in
table III. The mean level of serum ACTH for 51 male subjects was
30.1 pg/cm , and there was less than 1- picogram difference between morn-
ing and afternoon values. The mean afternoon serum value for 10 female
o
subjects was 26.k pg/cm (table IV). No morning serum samples from women
were analyzed. The average for all 6l subjects was 29-5 pg/cm .
When plasma and serum values were compared, there was no great dif-
ference in radioimmunoreactive levels of ACTH. The mean value for
105 subjects was 23.1 pg/cm plasma, and the mean serum value for 6l sub-
jects was 29.5 pg/cm . There was no detectable difference in the after-
noon plasma and serum levels. The mean for both afternoon values was
28.k pg/cm (table V). There was a difference in the morning values.
The lowered plasma levels may be a reflection of time or method of col-
lection for the female-subject samples not referred to in table III.
It is of interest that the mean afternoon value for ACTH did not
follow the traditionally described pattern of ACTH secretion (for ex-
ample, high morning levels followed by a gradual decline during the rest
of the 2U-hour period). If a downward trend was constant, then the
afternoon values should have been significantly lower than early morning
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values. -The occurrence of additional peaks of ACTH secretion throughout
a 2U-hour study of four normal subjects is shown in reference 3. The
relative consistency of values reported here could reflect such peaks of
hormone secretion during the daytime hours.
The anticipated circadian rhythm of ACTH secretion appears to be
altered when certain activities are imposed on the individual studied.
In one chamber study of an abnormal work/rest cycle, the expected 2k-haur
rhythm of plasma ACTH was not shown (table VI) . During this 3-day simu-
lation of an Apollo lunar mission, a slight decrease in ACTH levels was
noted for each succeeding day. Although the 23.9-hour rhythm of hydro-
cortisone secretion persisted during the study (ref. h) , the highest
daily levels of ACTH were recorded after the imposed sleep period. These
findings are in agreement with those of Curtis and Fogel, showing that '
individuals subjected to random sleep schedules have secondary peaks of
adrenal steroid secretion after sleep and also have high early morning
levels.
CONCLUSIONS
Baseline values of immunoreactive ACTH were established in the nor-
mal healthy adult. Normal levels of ACTH secretion were determined for
both the male and the female in circulating plasma and serum. The data
obtained in these studies are particularly significant in that the sam-
pling was carefully controlled; only healthy employed individuals of both
sexes were tested in a routine work situation that would not be consid-
ered conducive to stress. These data are of additional importance because
of the uniformity in time of collection and because the samples were ob-
tained under similar conditions by the same trained personnel.
It has been found that alterations in the classically described cir-
cadian rhythm of ACTH secretion can occur when activities (such as work/
rest cycles) are imposed on the individual studied. These changes can
be demonstrated even when there is no appreciable change noted in the
rhythm of hydrocortisone secretion.
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TABLE 5-1.- RADIOIMMUNOASSAY OF NORMAL HUMAN PLASMA ACTH
Subjects
Males
Females
Number
76
29
Age
2*t to 6l
16 to it5
Plasma ACTH range,
o
Pg/cm
0.19 to 127- it
it. 6 to 55-^
Mean ACTH level,
0
pg/cm
25.0
18.1
level of plasma ACTH for 105 subjects =23.1 pg/cm .
TABLE' 5-II-- MORNING AND AFTERNOON NORMAL HUMAN PLASMA ACTH LEVELS
Subjects
Males
Morning
Afternoon
Females
Morning
Afternoon
Number of
subjects
65
11
2it
5
Plasma ACTH range,
pg/cm
0.19 to 127.it
13.2 to 78.2
It. 6 to 39-2
6.8 to 55- U
Mean ACTH level,
pg/cm
23.9
31-7
17.it
21 . 3 -
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TABLE 5-V.- COMPARISON OF PLASMA AND SERUM
LEVELS OF IMMUNOREACTIVE ACTH
5-7
Source of specimen
Plasma
Concentration, pg/cm
Number of specimens
Serum
Concentration, pg/cm
Number of specimens
Time of specimen collection
Morning
22.1
89
30. 3a
3U
Afternoon
28. k •
16
28. U
27
No values for female subjects.
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TABLE 5-VI.- LEVELS OF ACTH SECRETION FOR ONE INDIVIDUAL
DURING AN IMPOSED WORK/REST STUDY
Day
1
2
3
Time
0630
081*5
2020
0505
0655
1730
0230
01*25
1U15
2230
Preceding event
Sleep
2 hr 100 percent oxygen
7 hr EVAa
Sleep
2 hr 100 percent oxygen
7 hr EVA
Sleep
2 hr 100 percent oxygen
6 hr EVA
Sleep
ACTH, pg/cm3
1*0.1*
27.8
15-2
28.0
19-9
22.8
23.0
16.1*
l6.U
16.2
Extravehicular activity.
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Extracted assay for ACTH
Lerner h-ACTH standard
Wellcome antiserum 1:30 000
125.Ih-ACTH
10 100
ACTH, pg/cm3
1000 2000
Figure 5-1.- Typical percent binding standard curve for radioimmunoassay
of ACTH.
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6. STUDIES OF THE RENIN-ALDOSTERONE SYSTEM AND SODIUM
HOMEOSTASIS DURING SIMULATED WEIGHTLESSNESS:
APPLICATION OF THE WATER IMMERSION MODEL TO MAN
By Murray Epstein, M.D.
INTRODUCTION
Theoretical considerations have suggested that the exposure of
astronauts to prolonged periods of gravity-free environment causes-
abnormalities of sodium and volume homeostasis (refs. 1 and 2). .Recent
reports on the Gemini VII (ref. 3) and Biosatellite III orbital-flights
(ref. U) have indeed borne out this concept, demonstrating a significant
natriuresis and weight loss following manned space flight. If a contem-
plated space shuttle system with orbiting space stations necessitating
prolonged human habitation is to become feasible, the heretofore unex-
plained severe volume depletion associated with weightlessness must- be
defined clearly, and specific countermeasures must be applied toward its
management. • • - . - •
Because of the inherent difficulties in performing inflight physio-
logical investigations, investigators have resorted to the use of the
models of absolute bedrest (refs. 5 and 6) and water immersion (refs. 1
and 2) are used as analogs of the zero-g state. Both analogs are thought
to produce a diuresis and natriuresis by producing a redistribution of
blood volume with relative engorgement of the heart and intrathoracic
vessels; these responses are similar to those that occur during weight-
lessness. However, the relative degree of redistribution induced by
immersion is thought to exceed that induced by absolute bedrest (ref. .7).
Thus, despite its limitation, the tendency of water immersion to exag-
gerate the anticipated hemodynamic effects of zero-g renders it an
excellent investigative model .for studying the circulatory mechanisms of
plasma-volume control during weightlessness.
Recently, the effects of water immersion on plasma-renin..activity,
aldosterone excretion, and renal-sodium handling in normal man have been
assessed under conditions carefully controlled for sodium and potassium
balance, posture, and time of day (refs. 8 to 10). ...
6-2
DISCUSSION
Studies of plasma-renin activity, urinary-aldosterone excretion, and
renal sodium and potassium excretion were conducted on eight subjects on
the fifth, sixth, and tenth days of dietary-sodium deprivation, when all
subjects achieved sodium balance (ref. 8). Control studies were conducted
on day 5 of the low-salt diet and immersion studies were done on day 6
and 10. Four subjects were immersed to the level of the umbilicus (waist
immersion) on day 6 and to the level of the sternoclavicular notch (neck
immersion) on day 10. The remaining four subjects were immersed to the
neck on day 6 and to the waist on day 10. Immersion was done in a water-
tank 2.13 meters long, 1.22 meters high, and 0.71 meters wide-(7 feet
long, It feet high, and 2 feet h inches wide). A constant temperature of
307 ± 0.5° K (31! ± 0.5° C) was maintained by two heat exchangers that had
a combined output of lU 233 725 joules/hr (13 500 Btu/hr) and that was
controlled by an adjustable temperature-calibrated control meter, the
input to which was derived from two thermistors immersed at different
water levels.
The effect of water immersion on the rate of sodium excretion (U,T V)
r)a
is shown in figure 1. During control studies with the subjects seated
but not immersed, U V was remarkably stable over the 6-hour period of
the study. Waist immersion did not alter U V. By contrast, neck immer-
iJ £L
sion produced a progressive increase in U V, beginning with hour h of
study. At 6 hours, U V was 20-times greater than that which was docu-
1M 3.
merited during either.control or waist immersion.
The effect of water immersion on plasma-renin activity (PRA) is
shown in figure 2. Plasma-renin activity was measured in blood samples
obtained at 2-hour intervals during each of the studies described. Waist
immersion produced a decrease of 1/3 in PRA at 2 hours (compared with the
preimmersion value), and this decrease persisted at U and 6 hours. Neck
immersion produced an even greater suppression of PRA, and values were
significantly lower than control and waist immersion both at h and 6 hours.
Because the observed decrease in PRA could have been the result of
an immersion-mediated decrease in renin-substrate concentration, renin-
substrate levels were measured. Values of renin substrate did not change
significantly in subjects immersed to the neck (fig. 3), showing that
suppression of PRA observed was not attributable to a decrease in sub-
strate concentration.
The effect of water immersion on the aldosterone excretion rate
(AER) was determined on pooled 2-hour urine specimens during each of the
study periods; the double-derivative isotope technique of Kliman and
Peterson was used. Aldosterone excretion during waist immersion was not
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significantly different from the control (fig. U). By contrast, neck
immersion resulted in a 2/3 decrease in AER during hours 3 to H, and
the decrease persisted for the remainder of the study.
An examination of changes in renal-potassium handling during immer-
sion contributes to further elucidation of the mechanism of the encount-
ered natriuresis. -During the control run, the rate of potassium excretion
(U V) remained relatively stable (fig. 5). By contrast, waist immersion
was associated with an increase in IL.V beginning with the hour 3 and
K. '
persisting thereafter. Neck immersion produced an even more profound
increase in UV, exceeding both control and waist immersion during peri-ls.
ods two through four. The documentation of an increase in UV at a time
K. ' .
when AER was significantly suppressed suggests that the suppression of
renin-and aldosterone are not likely to be the only etiologic factors in
t h e natriuresis that w a s observed. - • : . . ; .
'Because several lines of evidence had .suggested that adrenocorticp-
trophlc hormone (ACTH) plays a role in the physiological control •••of/••
aldosterone release (ref. 11), It is not clear whether the suppression,
of the renin-aldosterone system during immersion was selective or repre-
sented a generalized suppression of adrenocortical secretion mediated by
way of the pituitary-adrenal axis. Furthermore, because Lipman et al.
(ref. 12) recently showed a generalized decrease in pituitary-adrenal
reserve after 2 weeks of absolute bedrest, it was possible that adreno-
cortical secretion may be affected similarly during water immersion.
Thus, further studies were conducted to assess the effects of water im-
mersion on both aldosterone and IT-hydroxycorticosteroid (IT-OHCS)
release in normal man under identical experimental conditions of sodium
and potassium balance, posture, and time of day (ref. 9).
The effect of neck-level water immersion on AER is shown in fig-
ure 6. During quiet sitting, AER was relatively stable over the 8-hour
period of study, with values ranging from k.3 to 5.0 yg/hr. By contrast,
AER was significantly lower throughout the i^ -hour period of neck immer-
sion and the initial 2 hours of recovery.
Changes in PRA during neck immersion (fig. 7) paralleled tlipse
changes occurring in urinary aldosterone and showed a 30 percent decrease
after 2 and U hours of immersion compared with the preimmersion values
(p < 0.05). By the second and fourth hours of recovery, the level in-
creased slightly above control levels. By contrast, immersion did not
significantly alter plasma IT-OHCS levels. The mean plasma 17-OHCS
levels during control ranged from an initial value of 18.7 Mg percent
to Ik yg percent after 8 hours, reflecting the anticipated decrease occur-
ring during the day as a result of the diurnal rhythm in adrenal-steroid
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secretion. At hours 2 and k of immersion, when PRA was clearly suppressed,
plasma 17-OHCS was not significantly different from the control (p .> 0.3)
and, again, reflected the expected diurnal fall.
These data show that the suppression of the renin-aldosterone sys-
tem occurring during neck immersion appears to "be selective and not a •
manifestation of a generalized decrease in adrenocortical activity.
Furthermore, because plasma 17-OHCS levels closely parallel changes in
plasma ACTH (ref. 13), the constancy of plasma and urinary 17-OHCS
observed during control and immersion periods strongly suggests that
immersion under the conditions studied is not attended by significant
alterations in circulating ACTH. Therefore, this study further supports
the concept that the changes observed during immersion are specifically
related to alterations in the renin-aldosterone system.
Although the precise mechanisms remain to be elucidated, the ability
of water immersion to reproducibly suppress renin and aldosterone and to
produce a significant natriuresis suggests that the water-immersion model
may constitute a useful investigative tool for elucidating the mechanism
of the natriuresis occurring during manned space flight and the specific
countermeasure for use in its management.
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Figure 6-1.- Comparison of rates of sodium excretion during control and
6-hr vater immersion for eight subjects. Note that despite identical
sodium balances, tlT V increased significantly during neck immersion,Na .
in contrast to the stable levels of U V occurring during control and
. IN 3, .
waist immersion. Brackets represent mean ± standard.error, (ref. .9).
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Figure 6-2.- Serial changes in PRA in seven normal subjects during control
and in eight additional subjects undergoing both waist and neck immer-
sion (6 hr). All studies were done using identical water loads, so-
dium and potassium balances, seated body positions, and at identical
times of day. Brackets represent mean ± standard error (ref. 9).
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Figure 6-3.- Relationship of PRA and renin substrate during neck immer-
sion. Note the constancy of renin substrate at a time when PRA is
suppressed. Brackets represent mean ± standard error.
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Figure 6-U.- Comparison of changes in urinary-aldosterone excretion dur-
ing control and water immersion for eight subjects. Note the signif-
icant suppression of aldosterone excretion during the last U hours,
compared with control and waist immersion (ref. 9). Brackets rep-
resent mean ± standard error.
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Figure 6-5-- Comparison of rates of potassium excretion during control
and water immersion. Note the increases in IL.V during waist and
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mean ± standard error.
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Figure 6-6.- Comparison of changes in urinary-aldosterone excretion dur-
ing control and during neck-level water immersion. Aldosterone ex-
cretion was decreased significantly during immersion and during the
initial 2 hours of recovery (ref. 10). Brackets represent mean ±
standard error.
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jects undergoing water immersion to the neck level. The significant
suppression of PRA at hours 2 and h occurred independently of changes
in plasma 17-OHCS (ref. 10). Brackets represent mean ± standard
error.
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7. DEVELOPMENT OF SENSITIVE AND DIRECT METHODS FOR
MEASURING PLASMA ALDOSTERONE AND CATECHOLAMINE
CONCENTRATIONS
By Edgar Haber, M.D.
INTRODUCTION
The human circulation is regulated via two major pathways: vasomotor
reflexes and hormonal control. The principal hormones involved are angio-
tensin, aldosterone, and the catecholamines. To date, the role in homeo-
stasis of these substances is but incompletely understood. A major
obstacle has been the inability to measure blood levels conveniently and
repetitively in man under a variety of physical stresses. The advent of
a sensitive radioimmunoassay for renin activity, angiotensin I (ref. l),
and angiotensin II (ref. 2) has given new insight into the role of the
renin system in maintaining postural homeostasis (ref. 3). This was the
first demonstration that renin concentrations are changed within minutes
in response to alterations in effective blood volume. Unfortunately,
similar studies with aldosterone and catecholamines have not been
possible because of the large volumes of blood needed for these measure-
ments, which exclude repetitive sampling without risk of the experiment
itself inducing a hemodynamic change. This report describes laboratory
work contributing to the development of simple and very specific assay
procedures for aldosterone and catecholamines that may be conducted on
small volumes of blood.
ALDOSTERONE
Background
A number of methods are presently available that depend either on
double-isotope-derivative techniques or radioimmunoassay. The former
methods are relatively insensitive because of the large losses incurred,
generally requiring 25-50 cubic centimeters of blood. After extraction
of aldosterone, a series of chromatographic procedures is carried out
which serves to separate aldosterone from other steroids. Low produc-
tivity is a consequence of the many manipulations because a single
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technician generally is capable of only 20 determinations per week.
Radioimmunoassay procedures have offered some improvement in sensitivity,
though the specificity of the antisera is low, with the same chromato-
graphic procedures being required before measurement.
Antibody Specificity
In figure 1, the structure of aldosterone together with two steroids
of closely related structure (cortisol and corticosterone) is shown.
Although it is possible to conceive of an antibody of sufficient specific-
ity to differentiate among these compounds, the problem is magnified
because the concentration of aldosterone in plasma is approximately
50 pg/cm , while the concentrations of corticosterone and cortisol are
3
10 000 and 100 000 pg/cm , respectively. Consequently, the measurement
of aldosterone in the presence of these other compounds without prior
separation requires an antibody of extreme selectivity.
The displacement of labeled aldosterone from an antibody by the
unlabeled compound as well as by several other steroids is shown in
figure 2 (ref. k). This is clearly a very sensitive and selective
antibody, capable of quantifying aldosterone at picogram levels and
discriminating between this steroid and others by a factor of 100.
Unfortunately, this degree of discrimination is insufficient when the
other steroids exceed the concentration of aldosterone "by factors of
many thousands. Consequently, a detailed examination of three methods
of coupling aldosterone to protein carriers was undertaken, and the
antibodies raised to these antigens were critically studied.
Synthesis of Antigens
Aldosterone was reacted with p-hydrazinobenzoic acid, which previously
had been shown to react exclusively at the A3-^ position (ref. U). The
carboxyl group of the hydrazone then was allowed to react with bovine
y-globulin by the use of a carbodiimide reaction.
Aldosterone was allowed to react with carboxymethyl hydroxyl oxime,
under mild conditions, which formed an oxime at positions 3 and 20. The
carboxyl group of the oxime then was allowed to react with bovine
y-globulin by the use of a carbodiimide condensation.
Aldosterone 21 hemisuccinate was purchased from Yeda, Inc. and
subjected to a carbodiimide condensation with bovine y-globulin. This
procedure resulted in specific binding of the steroid to the protein at
position 21. The site of substitution of each of these derivatives is
indicated in figure 3.
7-3
Immunization
Each antigen was emulsified with .complete Freund adjuvant and
injected into the footpads of rabbits. Booster injections were given at
two weekly intervals, and blood samples were collected before each
injection
Radioimmunoassay
H-aldosterone (specific activity 20-50 Ci/mmole) was purchased from
New England Nuclear Company. In a typical assay procedure, diluted anti-
serum, H-aldosterone (specific activity 20 to 50 Ci/mmole), and varying
amounts of unlabeled aldosterone were incubated at 277° K (U° C) for
18 hours in a final volume of 1 cubic centimeter. At the end of this
time, charcoal (Norit A) that was suspended in a dextran solution was
added, and the tubes were centrifuged at 3000-g. The supernatant solution
was added to Bray solution and counted in a liquid scintillation counter.
Comparison of Antisera
Typical experiments for each of the three types of antisera elicited
are shown in figures k, 5, and 6. In these plots, the displacement by
aldosterone and several other steroids of rl-aldosterone from antibody is
compared. Antisera elicited by either the antigen linked at position 21
(succinate) or by the antigen linked at position 3 (hydrazone) are
relatively nonspecific. Although they possess adequate sensitivity
(50 picograms of aldosterone will achieve approximately 50 percent
displacement of label in each instance), there is sufficiently marked
cross-reactivity with other steroids so that use in a direct radio-
immunoassay is not feasible. However, an examination of figure 6
indicates that the antiserum raised to the dioxime antigen (aldosterone
bound to protein at positions 3 and 20) yields a displacement curve
characterized by both adequate sensitivity and extreme specificity.
Whereas 50 picograms of aldosterone are sufficient to achieve 50 percent
displacement of label from antibody, there is no significant cross-
reactivity with other steroids tested, even up to concentrations of
/- - C
10 pg/cm . Cross-reactivity is substantially greater than one part in 10 ,
Of six rabbits immunized with the dioxime antigen, three yielded
antisera of similar specificity, indicating that the experiment shown in
figure 6 does not reflect a rare or unusual response.
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Plasma Aldosterone Determination
The dioxime antisera may be used in a direct plasma radioimmunoassay.
One-tenth cubic centimeter of an aldosterone-free human serum or plasma
may be added to a final incubation volume of 1 cubic centimeter contain-
ing diluted antiserum and H-aldosterone without significant interference
of displacement of labeled by unlabeled aldosterone. Plasma from
adrenalectomized humans results in no displacement of label.
A critical comparison was made between the direct assay procedure
and a procedure dependent on chromatography, isotope dilution, and a
final radioimmunoassay step. A wide variety of patient samples having
both high and low circulating levels of aldosterone was studied. There
was remarkable agreement between the two methods. A correlation
coefficient, r = 0.92, was achieved.
A substantial simplification in the determination of aldosterone by
radioimmunoassay has been achieved, allowing accurate measurement of small
blood samples (0.1-cubic centimeter of plasma) with speed and increase
in productivity. It is anticipated that this will promote kinetic in-
vestigations of the role of this hormone in human vasoregulation.
CATECHOLAMIKES
Background
As with aldosterone, currently available methods for the determina-
tion of plasma concentrations of catecholamines lack sensitivity, are
cumbersome, and often are nonspecific, particularly in methods in which
fluorescence is used. A radioimmunoassay is unlikely to provide anti-
body of sufficient resolution because of the small size and relative
simplicity of the norepinephrine molecule. Consequently, efforts were
directed at identification of the physiological receptor because it was
clearly capable of differentiating between norepinephrine and its inactive
metabolites.
Isolation of the Receptor
The heart is an organ of substantial mass in which all of the
constituent muscle may be stimulated by norepinephrine. Consequently,
this should provide a rich source of catecholamine receptors.
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The left ventricle of the canine heart was homogenized with a
Teflon pestle and larger particles sedimented at 30 000-g for 5 minutes.
The supernatant then was centrifuged at 100 000-g for 1 hour, and the
pellet was collected. After resuspension in saline and a second centrif-
ugation, particles could be stored at 253° K (-20° C) indefinitely (ref. 5)
Radiodisplacement Assay
Particles were suspended in phosphate-buffered saline and incubated
with H-norepinephrine (370 disintegrations/second/mmole (10 Ci/mmole,
New England Nuclear)) for 1 hour. Following incubation, particles were
collected on a 0.22p millipore filter. The filter was placed in a scin-
tillation vial containing Bray solution, and particles were counted.
3
Particles effected a thirtyfold concentration of H-epinephrine from the
3
medium. Unlabeled norepinephrine competed with H-norepinephrine for
binding sites.
Specificity
The particle binding site appears to have the specificity of the
B-adrenergic receptor of the heart. In figure 7, the relative efficacy
of five B-active agonists in displacing H-norepinephrine from particles
is shown. Isoproterenol is most effective; whereas, epinep'hrine and
norepinephrine are less effective. This is in accord with the relative
potency of these compounds in affecting the rate and force of contrac-
tion of the heart. The information in figure 8 indicates that the
a-active or indirectly B-active catecholamines are much less effective
or are ineffective in competing with H-norepinephrine. In figure 9,
it can be seen that the 3-blocking agent, propranolol, can displace
H-norepinephrine from particles; the a-blocking agent, phentolamine,
cannot perform this function. In addition, it can be shown that metabo-
lites of catecholamines, such as metanephrine and nor-metanephrine are
ineffective in competing with norepinephrine, even at very high concen-
trations. The information in figure 10 shows the specificity of the
receptor as deduced from studies of interaction with a variety of analogs
of catecholamines.
Development of a Radioreceptor Assay
)le to measure 1 to 2 ng/cm of eithei
norepinephrine in aqueous solution with reproducibility and specificity.
It is possible r epinephrine or
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A direct plasma assay has not been possible because of nonspecific inter-
ference by plasma constituents. Procedures are being developed for
rapidly extracting catecholamines from plasma so that they may be
measured in the radioreceptor assay.
SUMMARY
A new tool has become available in the study of vasomotor regulation,
and another is soon to become available. It now should be possible to
answer important questions concerning the relative roles of the nervous
system and circulating hormones in maintaining vascular volume and
pressure homeostasis.
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Figure 7-1.- Structures of aldosterone, corticosterone, and cortisol.
C,g (R ) aldehyde of aldosterone exists in solution in a hemiacetal
link with the C.,., (ref. U). - • .
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Figure 7-2.- Displacement of H-aldosterone by n-aldosterone and by other
steroids. Incubation mixtures contained 21 picograms of H-aldosterone
and a 1:150 dilution of serum from rabbit number 8lO, obtained 10 weeks
after initial immunization. In the absence of nonlabeled steroids,
6l percent of the H-aldosterone was bound by the antiserum.
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Figure T-3.- Structure of aldosterone with schematic indication of the site
of substitution of the reagents studied. Oxim is carboxymethyl hydro-
xyloxime; succinat is succinate; hydrazon is p-hydrazinobenzoic acid.
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Figure T-^ .- Displacement of H-aldosterone from a typical antiserum raised
with the 21-aldosterone hemisuccinate conjugate.
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Figure T-5-- Displacement of H-aldosterone from a typical antiserum raised
with the A3-U hydrazone conjugate.
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Figure 1-6.- Displacement of H-aldosterone from a typical antiserum raised
with the A3-1*, 20 dioxime conjugate. ,• •
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Figure 1-1.- Inhibition of [3H] norepinephrine binding to cardiac microsomes
by B-adrenergic agents (ref. 5).
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Figure 7-8.- Inhibition of [ H] norepinephrine binding to cardiac microsomes
by ot-adrenergic agents and indirectly active g-adrenergic agents (ref. 5).
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Figure 7-9.- Inhibition of [ H] norepinephrine binding to cardiac microsomes
by adrenergic blocking agents. Each point is the mean of duplicates
(ref. 5).
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8. PARATHYROID HORMONE, CALCITONIN, AND VITAMIN D
By John T. Potts, Jr., M.D.
PARATHYROID HORMONE
Determination of the complete amino-acid sequence of the major form
of the bovine parathyroid hormone (BPTH) (refs. 1 and 2) (fig. l) and the
development of a new technique have permitted preparation of numerous
synthetic peptides related to parathyroid hormone (PTH) (refs. 3 and h.)
as part of systematic studies of structure-activity relations. The suc-
cessful synthesis (ref. 3) of a biologically active amino-terminal 1-3^
fragment' of the bovine parathyroid-hormone sequence c'onfirmed the earlier
observation (ref. 5) that the entire'Qh amino-acid sequence was not re-
quired for biological activity. The synthetic tetratriacontapeptide was
found to possess qualitatively all the specific physiological and bio- '
chemical properties associated with native parathyroid hormone (ref. 3).
Studies done with fragments of the native molecule indicated that
the sequence 1-29 is sufficient for biological activity (ref. 6). Also,
synthetic peptides were prepared corresponding to the sequences 1-30, ••
1-28, and 1-27 of the bovine molecule and to the sequence 1-30 of the
porcine molecule (ref. U). All sequences were active (fig. 2). However,
the fragment 1-20 was completely inactive in the adenyl cyclase assay
(ref. 6). Whether tested separately or together, the synthetic fragments
1-13, 1U-3U, 19-3U, and 25-3U also were biologically inactive (refs. 3
and h). Deletion of the amino-terminal residue alanine (as in the syn-
thetic fragment 2-3^) led to a complete loss of biological activity
(refs. 3 and 6). In addition, carboxyl-terminal fragments 26-1+5, ^6-52,
and 53-8U, derived from tryptic digestion of e-aminolysine-blpcked"native
parathyroid hormone, were completely void of biological activity (ref. 7).
These findings define the minimum requirements of. the biological effects
of bovine parathyroid hormone as being present in a continuous sequence
that extends at least 20 residues from the amino-terminal alanine (resi-
due l) to a point somewhere between arginine (residue 20) and lysine' '
(residue 27). Detection of significant biological activity for the pep-
tide norluen (l-30 porcine) , a peptide devoid of methionine, has estab-
lished that methionine is not essential for biological activity (ref. 6).
The immunoassay for parathyroid hormone (refs. 8 to ll) has been
refined and improved considerably. This work resulted from improvement
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in the techniques used to purify the radioactive parathyroid hormone
used in the immunoassay and by the development of a series of valuable
antisera of sufficient sensitivity for use in detection of parathyroid
hormone in human blood but with the added advantage of reaction with
different areas of the linear sequence of parathyroid'hormone (ref. 12)
(figs. 3 and U). With the addition of these antisera to those used pre-
viously in radioimmunoassay studies, a battery of selective reagents
exists with which the recently recognized problem (refs. 13 to 15) of
different circulating fragments of parathyroid hormone in blood can be
analyzed (figs. 5 and 6). Recently, greatest interest has centered on
findings that the biosynthesis, secretion, and metabolism of parathyroid
hormone is much more complex than believed previously (refs. 12 and 13).
The existence of a biosynthetic precursor to parathyroid hormone in human
and bovine glands has been established (refs. l6 and IT) (fig. 7). In-
tracellular cleavage and storage of the prohormone appears to be in anal-
ogy with the conversion of proinsulin to insulin. A second cleavage of
the 1-8U intact hormonal peptide in one or more peripheral organs occurs
after release (refs. 12 and lU). Contrary to earlier reports, the hor-
mone is released intact from the parathyroids; the cleavage to apparently
inactive fragments represents a peripheral mechanism concerned with hor-
mone destruction (refs. 12 to lU) (figs. 6 and 8). These findings ex-
plain much of the present confusion concerning clinical immunoassay
studies. However, even at present, many useful clinical studies can be
undertaken using radioimmunoassay (refs. 18 to 2^ ).
Analyses of secretion of parathyroid hormone during tests of stimu-
lation and suppression of hormone-secretory activity using infusions of
n
EDTA and calcium, respectively, have established that, in contrast to
previous views, secretion of the hormone is not autonomous in many pa-
tients that have adenomatous hyperparathyroidism, but is responsive to
changes in blood-calcium concentration (ref. 19). These findings have
led to a new understanding of the pathophysiology of hormone production
in hyperparathyroidism.
A related application of the diagnostic use of the radioimmunoassay
is the preoperative localization of parathyroid tumors and the distinc-
tion between adenomas and chief-cell hyperplasia (refs. 18 and 23). Work
involving catheterization'and radioimmunoassay of blood samples obtained
from'the subclavih and innominate veins and the venae cavae, led to lo-
calization in a high percentage of patients (fig. 9). However, this
procedure has been adopted recently to detect hormone concentration in
the small veins directly draining the parathyroid glands. This detec-
tion has resulted in a great increase in sensitivity and in general
utility of the technique (table l).
J^thylenediaminetetraacetic acid.
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CALCITONIN
Multiple immunoassay systems, suitable for specific detection of
salmon, ovine, porcine, and human calcitonin, have been developed suc-
cessfully (fig. 10). By the use of these techniques, the control of
calcitonin by blood calcium has been analyzed, and the fact has been
established that calcitonin production is under directly proportional
control by blood-calcium concentration (ref. 25). Studies in numerous
animal species (refs. 20 and 26) have established many important physi-
ological aspects of calcitonin secretion, including the quantitative
response to hypercalcemia, the role of new hormone biosynthesis, and the
metabolic clearance rate of the peptide.
In the porcine species, the secretion of calcitonin is directly
proportional to the blood-calcium concentration (ref. 26). This species
also has served as a model to study the effect of other factors on cal-
citonin secretion. Gastrointestinal hormones, such as glucagon and gas-
trin, have been shown to stimulate the secretion of this peptide
(ref. 20).
The secretion of calcitonin also has been studied in the bovine
species by means of radioimmunoassay (ref. 27). Preliminary studies
have indicated that the concentration of calcitonin in the blood of bulls
is significantly higher than that in the blood of cows (fig. ll). • This
fact may be related to the high dietary calcium that is required in.bo-
vines to meet the needs of cows that incur losses of calcium through
pregnancy and lactation. However, bulls, that ingest the same calcium'
load as cows, must compensate for this large dietary-calcium challenge.
Presumably, the increased plasma calcitonin in bulls represents a com-
pensatory response of the calcitonin-secreting cells to maintain blood
calcium within normal limits despite the dietary-calcium challenge.
These observations take on more importance when considering the increased
incidence of carcinomas of the calcitonin-secreting cells in bulls.. As
many as 30 percent of the bulls older than 6 years have such malignancies.
The incidence of these malignancies is related to the prolonged dietary-
calcium challenge in these animals.
Studies also have been conducted to determine the importance of cal-
citonin in salmon (ref. 28). The hormone plays some role in the migra-
tion of salmon from fresh to salt water and vice versa. In general,
calcitonin concentrations are increased in salmon in salt water compared
with salmon in fresh water; this fact may represent a homeostatic response
to prevent the blood calcium from rising to dangerously high levels when
the fish migrate into salt water. An anticipated finding in the salmon
is the difference in calcitonin secretion between the sexes; the concen-
tration of peptide is significantly higher in females than in males. In
8-U
the female, a progressive rise in calcitonin secretion is evidenced from
the time of entry into fresh water to the time of spawning. After spawn-
ing, a precipitous drop in calcitonin concentration occurs. The signif-
icance of these findings is under further investigation.
The rate of calcitonin secretion in man has been clarified, cor-
recting earlier overestimates (refs. 29 and 30). If secreted at all,
calcitonin is produced in normal man at concentrations much below that
in other mammals (fig. 12). The human-calcitonin assay has been applied
to the measurement of calcitonin production in patients that have medul-
lary carcinoma of the thyroid (fig. 13); the assay has been proven to be
extremely valuable in the early detection of this malignancy. Because
patients with medullary carcinoma of the thyroid have increased concen-
trations of calcitonin, the assay is an accurate procedure for the estab-
lishment of the diagnosis of this tumor in affected patients (ref. 31).
This procedure allows for early diagnosis of the malignancy and for po-
tential patient cure by means of surgery. Although not a common tumor,
medullary carcinoma of the thyroid often has a familial distribution;
therefore, the relatives of affected members can be screened so that
early diagnosis may be made.
The secretion of calcitonin also has been studied in hypocalcemic
patients (fig. 1*0. These subjects have increased stores of calcitonin
in their thyroid gland, presumably promoted by the hypocalcemia (ref. 20).
Upon appropriate stimulation, these calcitonin stores are released in the
peripheral 'circulation where they can be detected by the use of immuno-
assay. These patients have been very important for studying the control
of peptide secretion in subjects other than those with medullary thyroid
carcinoma. With the exception of patients with medullary thyroid carci-
noma, it is only in hypocalcemic human subjects that calcitonin can be
detected readily in the peripheral circulation of humans.
Because the concentration of this peptide presumably is so low,
special means will be necessary to study the secretion of this peptide
in man (other than in patients with medullary thyroid carcinoma). One
of the proposed approaches is the use of immuneabsorbant chromatography
to concentrate the calcitonin in plasma samples (ref. 32). (For example,
calcitonin-specific antibody is attached to a solid phase-supporting
medium such as Sepharose). Then, plasma can be passed through this col-
umn, and any calcitonin in the plasma will be trapped by the antibody on
the column. Subsequent to the trapping of calcitonin, this peptide can
be eluted from the column and concentrated into a small volume. This
procedure should increase the effective sensitivity of human calcitonin
assay by several orders of magnitude. Associated with this procedure
should be the use of similar techniques to improve the actual sensitivity
of the calcitonin assay. By coupling calcitonin to a solid phase, it
will be possible to isolate from antiserum those species of calcitonin
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antibody that have the highest affinity for the hormone. These high-
affinity antibodies then can be used directly in the immunoassay
(ref. 33). Such procedures will allow the measurement of calcitonin
concentration in normal human subjects and the evaluation of the effect
of variables such as prolonged immobilization and weightlessness on cal-
citonin secretion.
VITAMIN D
Vitamin D is necessary for normal bone formation and remodeling and
for normal intestinal absorption of calcium. The availability of radio-
active vitamin D of high specific activity made possible the discovery
of the complex metabolism of vitamin D that occurs before the expression
of the physiologic action at the tissue level. Normally, the vitamin,
stored in the body after formation in the skin or absorption from the
diet, is converted to 25-OH vitamin D hydroxiecholecalciferal (25 HCC)
by a specific hydroxylase in the liver (ref. 3*0. Although this compound
is active in vitro (whereas vitamin D is inactive), the discovery has
been made that, in vivo, further hydroxylation of the vitamin occurs be-
fore it acts on target tissues. For example, 25-OH vitamin.D is metab-
olized in the kidney to 1,25-(OH)2 vitamin D dihydroxycholecalciferol
(1,25 DHCC) and to other dihydroxy metabolites that have not yet been
identified fully (ref. 35).
In recently reported work, the suggestion has been made that
1,25 DHCC is the form of the vitamin that acts to stimulate calcium . . r
transport by the intestine (ref. 36). The characteristic timelag be-;,,
fore increased calcium transport is manifest in the gut after.the admin-
istration of vitamin D or 25 HCC is reduced significantly after vitamin D
repletion with 1,25 DHCC. On a weight basis, this dihydroxy metabolite
also is more potent than either D or 25-OH D (ref. 37). Furthermore,
although pretreatment with actinomycin D abolishes the intestinal action
of both vitamin D and 25 HCC, it does not interfere with the intestinal
effect of 1,25 DHCC (ref. 38). Thus, the antibiotic probably interferes
with the metabolism of 25 HCC to the dihydroxy metabolites in the kidney
(ref. 39).- Presently, 1,25 DHCC is believed to be the intestinally
active form of the vitamin.
This compound also can act to mobilize bone calcium, and has a time
course somewhat faster than, but with a total effect no greater than,
25 HCC (ref. Ho). In mobilizing calcium from fetal-rat calvaria (D is
inactive in this system) (ref. ^l), 1,25 DHCC is more active than is
25 HCC. The dihydroxy metabolite is effective in mobilizing bone cal-
cium in anephric rats. The skeletal actions of vitamin D, 25 HCC, and
1,25 DHCC are blocked by actinomycin D (ref. ^0) treatment.
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A second dihydroxy metabolite, 21,25 (OH)? D, also facilitates
the mobilization of skeletal calcium in the vitamin D-deficient animal
but has only limited potency on intestinal calcium transport (ref. H2).
The physiologic significance of this metabolite has yet to be explained.
A third dihydroxy metabolite has been identified as 25,26 (OH)
vitamin D. Although this compound stimulates active transport of cal-
cium in the intestine, it does not mobilize bone calcium and is of un-
known physiologic significance (ref. U3). The data are suggestive that
the action of 1,25 (OH)2 D_ in bone requires further metabolism of the
vitamin or deoxyribonucleic acid (DNA) transcription to messenger
ribonucleic acid (mRNA) or protein synthesis; however, the action of
1,25 DHCC in the gut apparently involves stimulation of a preformed
transport mechanism.
The metabolic activation of vitamin D appears to be a regulated
process in both the liver and the kidney. In vitro experiments imply
product inhibition of the 25-hydroxylase in the liver (ref. 36); however,
in vivo formation of both 1,25 DHCC and an unidentified metabolite (peak
Vo) varies with the serum-calcium level. The formation of 1,25 DHCC by
the kidney occurs when the serum-calcium level is less than 9-2 percent;
however, formation of the peak Va metabolite occurs when the serum cal-
cium exceeds 9.5 percent (ref. U1+). The formation of one metabolite
seems to preclude formation of the other, indicating close metabolic
regulation based on the serum-calcium level or some other metabolic de-
terminant that varies with the serum calcium. The formation of 1,25 DHCC,
with subsequent stimulation of intestinal calcium transport, should be
associated with a lowered serum calcium. An intrinsic renal action has
been postulated for the peak Va metabolite but, as yet, no direct evi-
dence bearing on this issue is available.
Indirect evidence also suggests regulation of vitamin D activation.
The body adapts to increased calcium requirements (growth, pregnancy,
and lactation) or to a low-calcium diet by increased efficiency in the
absorption of dietary calcium (ref. *+5). This facultative increase in
absorptive efficiency is not dependent on the presence of parathyroid
hormone, calcitonin, growth hormone, or adrenal steroids, but is abso-
lutely dependent on the presence of vitamin D (ref. 1+6). As proved in
recent experiments, the regulation of vitamin D activation (specifically
the regulation of 1,25 (OH) vitamin D by the kidney) plays an important
role in this adaptation (ref. 1+7). Further indirect evidence supporting
regulation of vitamin D activation in man is the rarity of hypervitamin-
osis D despite wide variations in exposure to ultraviolet light and in
dietary vitamin D intake. In fact, induction of hypervitaminosis D (as
in the treatment of hypoparathyroidism) requires 50-100 times the minimum
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daily dose of the vitamin that is needed to prevent rickets (ref. 21).
In animals, a similar margin exists between the dose necessary to evoke
the maximum physiologic response and the dose necessary to produce the
manifestations of hypervitaminosis D on the skeleton or in the intes-
tines (ref. 21). Therefore, a reasonable hypothesis is that vitamin D
metabolism, is regulated, that this regulation occurs at one or more of
the points where metabolic conversion occurs, and that regulation of
vitamin D activation plays a role in homeostatic regulation of skeletal
calcium.
Using radioactive vitamin D and a specific D-binding plasma protein
(refs. hQ and 9^), the saturation-analysis assay is sufficiently sensi-
tive to detect physiological concentrations of endogenous vitamin D and
its active metabolites (fig. 15). This detection represents a potential
advance in studies of normal vitamin D physiology and disorders of vita-
min D metabolism in man. Already, the assay has been applied to the de-
tection of vitamin D_ and 25-OH vitamin D_ in man and in rats made D
deficient then repleted with various amounts of the vitamin. Many im-
portant aspects of the complex metabolic role of vitamin D, tissue-
specific products, and the vitamin D-binding protein can now be explored.
Vitamin D? (derived from diet supplements in foodstuffs) and vitamin D.
(formed by the action of light on precursor compounds in the skin) are
not of equivalent potency for displacement of radioactive vitamin D_
from the binding protein (fig. l6). The assay is approximately four
times more sensitive for the detection of D., than for Dp. This phenom-
enon prevents immediate application of the saturation-analysis assay in
its present form to detection of physiologic concentrations of the vita-
mins in normal human subjects wherein both vitamin D_ and D,, must be as-
sumed to be present in the circulation. Thus, efforts are necessary to
modify assay conditions to measure vitamin D? and vitamin D_ separately.
One approach to the separate estimation of vitamin Dp or D_ inde-
pendent of the presence of the other compound is the use of a binding
.protein that is extremely insensitive for the detection of one form of
the vitamin. Initial studies have been suggestive that such a binding
protein may be present in the chicken blood, and the binding of
vitamin D? by protein is extremely poor. Efforts will be made to inves-
tigate further the stability -and general applicability of the binding-
protein preparation prepared from chicken blood for specific assay of
vitamin D_. Another approach would be the development of antibodies
selective to vitamin D? and D,. and the use of these antibodies in a
radioimmunoassay system to measure these vitamins individually.
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Because the vitamin is derived from the diet and from the action of
light on a precursor in the skin, the estimation of the normal vitamin D
load (endogenous and exogenous) required to maintain normal skeletal me-
tabolism has not been possible. With normal environment, a normal diet,
and solar irradiation, this problem is>riot present except for certain
disease states in which excess exogenous vitamin D can cause symptomatic
hypercalcemia. In a completely closed environment and with an artifical
diet, it becomes very important to define the vitamin D requirements
necessary for normal skeletal homeostasis and to define any differences
between "natural" vitamin D (endogenous vitamin D ) and dietary vita-
min D. The newer assay techniques should facilitate better definition
of these important problems.
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TABLE 8-1.- VENOUS-CATHETERIZATION RESULTS
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e2.1
1.5
(g)
12.1
25^0.
.85
2JL
(g)
-
2.2
k.l
iii
. 21,0
5i2.
"2.2
Diagnosis
Right upper, adenoma
Left upper, adenoma
Left upper, adenoma
Left upper, adenoma
Right lover, adenoma
Left lover, adenoma
Right upper , adenoma
Right lover, adenoma •
Right upper, adenoma
Left lover, adenoma
Left lover, adenoma
Mediastinal adenoma
Double adenomas {left lover;
right lover)
Hyperplasia (left thyroid-
ectomy previously) •
Hyperplasia
Hyperplasia (previous sur-
gery; both upper glands
removed)
Hyperplasia
Hyperplaeia
Hyperplasia
Hyperplasia
Hyperplasia
formal range: 9*0 to 10.5 mg.
"Normal range: 0.3 to 0.8 ng/cn .
cMembera of a kindred with familial hyperparathyroidism.
All underlined values are significantly (P < 0.001) elevated above mean-peripheral level.
eP < 0.05.
Kypothyrold; thyroid veins tiny.
8Ligated.
hStump.
Had previous surgery that caused distortion and interruption of venous drainage.
Jprior arteriogram outlined the lesion and indicated the appropriate vein to Catherine.
*? < 0.1.
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Figure 8-1.- Amino-acid sequence of BPTH with amino-terminal alanine.
Amino-acid residues that differ betveen BPTH and porcine PTH are
indicated by the porcine amino acids in apposition.
1 13 20 29 30 34 44 52
ala—lys—arg—gin asp—phe-arg—arg-
1 34
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ala gin
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Figure 8-2.- Biological activity of natural and synthetic PTH fragments
(fragments 1 to 28 and 1 to 27 not shown).
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• BPTH
° 1 to 34 fragment
D 53to 84 fragment
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125,Figure 8-3.- Comparison of the fall of bound antibody to free """^ I-BFTH
tracer from antibody control (bound/free ratio in the absence of un-
labelled hormone) in assays using four antisera as a function of in-
creasing concentrations of BPTH and BPTH fragments.
0.9 r
• BPTH
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10'
•I pr
Figure 8-1+.- Inhibition of binding of ?I~BPTH tracer by increasing con-
centrations of BPTH, and BPTH fragment, and subfragments.
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Figure 8-5.- Inhibition of binding by increasing volumes of the same plasma
sample in assays using GP-133 and GP-1.
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Figure 8-6.- Radioimmunoassay results for immunoreactivity In fractions
after gel filtration of a peripheral plasma sample on Biogel P10 using
GP-1 preabsorbed with excess concentrations of fragment 53 to 8U (N)
and 1 to 3U (c). It is demonstrated that the dominant form of immuno-
reactive hormone in human circulation consists of a hormonal fragment
that is totally void of an antigenic determinant requiring the lk to 19
region of the hormone.
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Figure 8-7.- Comparison of the gel-electrophoretic position of hormone
15 and 60 minutes after exposure of human parathyroid adenoma tissue
slices in incubation media to C-labelled amino acids. The arrow
marks the position of human hormone extracted from glands. The elec-
trophoresis medium was 8M urea pH it.U gel. Note that at 15 minutes
lUthe peak of C-labelled material has migrated farther than the hormone
extracted from glands, indicating that this material is more basic. At
.. Hi
60 minutes,"the peak of C-labelled material cannot be distinguished
from the marker.
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Figure 8-8.- Radioimmunoassay results of the immunoreactivity in fractions
after- gel filtration of a plasma sample obtained from the parathyroid
venous effluent at the time of diagnostic venous catheterization. The
filtration was done on Biogel P-10, and the fractions were assayed with
GP-1 preabsorbed with 53 to 8U (N)'and.-l to 31* (c). The hormone'elutes
as a single peak coincident with the marker and has equivalent concen-
trations of amino- and carboxy-terminal reactivity, indicating that the
secreted hormone is identical to the hormone extracted from the glands.
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1 = innominate vein
Common IT = common inferior thyroid vein
J =jugular vein
LIT = left inferior thyroid vein
MT =middle thyroid vein
R1T * right inferior thyroid vein
ST = superior thyroid vein
SVC = superior venacava
Case 4
Heft upper adenoma)
Case 19
(hyperplasial
1.6IST)
2.1 IJI
9.2
(Common IT>
Figure 8-9.- Tracings,from thyroid venograms in patients U and 19; the
hormone results are shown on samples from the sites shown. In patient
19, both inferior thyroid veins join to form a common terminal trunk
before entry into the left innominate vein, showing that, in case U,
there is a step-up in the LIT but that, in case 19, hormone measurements
from both sides of the neck are elevated. These results indicate that,
in case U, there is a left-sided adenoma and that, in case 19, there is
multiglandular involvement. These facts were confirmed during surgery.
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Figure 8-10.- Each of the calcitonin iramunoassays is sufficiently sensitive
to detect peripheral concentrations of calcitonin in the appropriate
species. Note that significant cross-reactivity is. shown among the ;'s' '
.structurally similar porcine, bovine, and ovine calcitonin;' there''is '
little cross-reactivity among salmon, human, and the other calcitpnins.
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Figure 8-11.- Calcitonin concentrations in plasma samples taken randomly
from 29 bulls and l6 cows. The mean (±S.D.) concentration in bulls,
303 ± 13 pg/ml, is significantly (p < 0.01 (by student's t test)) higher
than the mean concentration, 165 ± 12 pg/ml in cows. There is no sig-
nificant difference in plasma-calcium concentration between cows and bulls
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o o o
Medullary thyroid carcinoma
• Control
O Post charcoal,
adsorption
Normal
• Control
O Post charcoal
adsorption
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Figure 8-12.- The use of charcoal adsorption to preclude artifactual dis-
placement of calcitonin from specific antibody by plasma samples. Char-
coal, demonstrated to adsorb > 10 000 pg/ml of calcitonin from plasma,
removed all detectable calcitonin from a plasma sample of a patient with
medullary thyroid carcinoma. As a result, the sample, which progres-
sively displaced tracer from antibody before charcoal adsorption, fails
to do so after adsorption. By contrast, there is no difference in the
displacement of tracer produced by a normal plasma ;sample before and
after charcoal adsorption. Therefore, the apparent calcitonin concen-
tration in this sample was artifactual and probably was caused by non-
specific displacement of tracer from antibody.
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Figure 8-13.- Plasma calcitonin in patients with medullary thyroid carcinoma
(surgically proven) and elevated hormone concentrations. Plasma calci-
tonin in normal subjects is less than 100 pg/ml, the detection limits of
the immunoassay system.
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O'Pseudohypopara thyroidism
• Idiopathic hypoparathyroidism
Figure 8-lU.- The increase in plasma calcitonin after calcium infusion in
patients with pseudohypoparathyroidism and idiopattiic-hypoparathyroidism.
In contrast to normal and hypercalcemic subjects, the patients have post-
infusion levels of hormone that can be detected readily.
i.o
• Vitamin 03
O 25-OH vitamin D3
10 20 30 40
Vitamin D, or 25-OH vitamin 0.. ng
Figure 8-15.- Competitive binding assay standard curves with vitamin D_ and
25-OH vitamin D .
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Figure 8-16.- Competitive "binding assay standard curves with vitamin D ,
vitamin D_ and dihydrotachysterolp.
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9. DISSOCIATION OF EFFECTS OF PROLONGED CONFINEMENT
AND BEDREST IN NORMAL HUMAN SUBJECTS:
HEART RATE AND BODY TEMPERATURE
By Charles M. Winget, Ph. D., Joan Vernikos-Danellis, Ph. D.,
Carolyn S. Leach, Ph. D., and Paul C. Rambaut, Sc. D.
The daily rhythm of human physiological functions is a complex re-
action, produced at least in part by adaptation of the organisms' to daily
changes in the earth environment. The complex, dynamic interrelation-
ships produced "by social and physical environmental- factors underlie' the '
formation of diurnal rhythms in human physiological functions. To eval-
uate the effects of simulated weightlessness on physiological systems, .'
the effect of restriction of muscular activity (bedrest) on certain "•
physiological rhythms was investigated in eight healthy male subjects
who were maintained in a defined environment. The results of this study
have been reported previously (ref. l). That study included a 6-day
ambulatory, prebedrest period; 56 days of bedrest; and a 10-day postbed-
rest recovery period. Four of the subjects exercised during bedrest.
Body temperature (BT) and heart rate (HR) and circulating cortisol'y
triiodqthyronine (T_), and thyroxine (T, ) concentrations were measured
at four hourly intervals throughout the study.
The results were indicative of the following changes. During bed- .
rest, mean HR increased, whereas BT and steroid outputs decreased. Nei-
ther exercise nor the 10-day postbedrest ambulatory period prevented or
corrected this effect. The HR remained more stable throughout bedrest
than did the other rhythms studied. By contrast, the amplitude of the
Ti rhythm appeared to increase as bedrest progressed, and the total
serum T_ concentrations increased during the latter part of the bedrest.
The data are suggestive that the daily change in phase and amplitude or
desynchronization of BT, T~, and T> rhythms were caused "by the position
of the body and that the observed low-grade hypothermia and minor tachy-
cardia were characteristic of the hypokinetic syndrome in man. In ad-
dition, most parameters did not show complete recovery by the end of the
experiment; that is, 10 days after the last day of bedrest. Furthermore,
on approximately day 20 of bedrest, all parameters showed some'changes...
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For example, the level of cortisol increased, as did the mean level of
T , and the phase angle of BT and HR shifted suddenly. A possible social
influence of the rhythms of one individual on those of another also was
suggested "by the results.
In a study of this type in which continuous data are obtained from
eight subjects during a period of 72 days, the problems of data analysis
and optimal representation becomes enormous. Therefore, to readily in-
form the observer concerning day-to-day dynamic phase and amplitude
changes, it was necessary to develop a method that expresses, in chart
form, rhythmic data that may be nonstationary in time. The summation-
dial method (ref. 2) was developed to meet the requirements. This is a
method in which the curve best fitting the data is derived mathematically,
assuming a specified period (for example, T = 2k hr). Each point on
the curve represents the end of a vector, which has a certain magnitude
and direction describing the phase of the rhythm for that day (fig. l).
The summation of these vectors or train of vectors produces the summa-
tion, dial (fig. 2). The direction of the vector train is determined by
the hour of the day at which estimated peak activity of that parameter
occurred. The length of the vector indicates the amplitude of the
rhythm.
Because this was the first study of this duration and because cer-
tain parameters changed radically over time and did not return to pre-
bedres.t values, it was necessary to conduct a second experiment to better
explain certain of these changes. The second study was designed to in-
clude a- longer prebedrest control and postbedrest recovery period. Be-
cause the second bedrest study involved confinement of young, healthy
males for prolonged periods, an equal group of equal number subjects
that were not put to bed were included. These subjects remained ambula-
tory and confined to the experimental area and were maintained on an
identical schedule.
Because exercise appeared to have little or no effect in the pre-
vious study, no exercise was included. In the previous study, the ques-
tion was raised whether some of the observed changes, particularly those
around day 20, may have been caused by the bleeding schedule. Therefore,
two subjects, one in the ambulatory and one in the bedrest group, were
not bled in this study. Only BT, HR, and urine data were collected
from these subjects. Several additional parameters were added to the
original study to better assess the changes and mechanisms in physiolog-
ical function produced by prolonged bedrest.
Twelve healthy males, age 20 to 26 years and weighing approximately
55.33 to 98.^ 1 kilograms (122 to 217 pounds), were divided into two groups,
The six subjects in group I followed an experimental procedure that in-
cluded a 20-day ambulatory prebedrest control period, 56 days of absolute
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bedrest, and a 20-day- postbedrest recovery period. The six subjects in
group II remained ambulatory for the entire 96 days but were confined to
the metabolic ward. The selection of the 12 subjects from the 50 to
60 applicants was based on interviews and psychological tests. All sub-
jects were on a lU-hour-light/10-hour-dark regimen (lights on at
0900 hours) and were fed a "balanced diet of 10 1*60 joules (2500 calories)
per day. Data were collected on HR and ear-probe temperature (BT)
12 times daily throughout the study.
The main characteristic of the data obtained from the ambulatory
subjects was the remarkable consistency. The HR was particularly con-
sistent, showing a peak at approximately 1700 hour,s in all six subjects,
and did not deviate throughout the study. The BT of this group was •
somewhat less stable; however, the peaks occurred in the same quadrant,
between 20U5 and 02^ 5 hours (figs. 3 and U). '
In the bedrest group (fig. 5), the HR data can be divided into
four segments. In the prebedrest period, the subjects showed stable
rhythms that were similar to the ambulatory group. In the first 3 weeks
of bedrest, a small but obvious phase shift of approximately 2 hours
occurred. Next, a second phase shift of approximately k hours occurred
and lasted for the remaining 5 weeks of bedrest. Finally, the rhythms
of postbedrest subjects almost immediately resynchronized with the orig-
inal prebedrest rhythms. The mean HR dropped initially and then in-
creased and remained elevated during the 20 days postbedrest.
During bedrest, the BT data were highly variable (fig. 6). The
temperatures of three of the subjects peaked in the same quadrant as
those of the ambulatory subjects, and peaks for the other three occurred
in the morning (l80 degrees out of phase). The BT data for all subjects
showed considerable rephasing throughout the bedrest; the BT data for
three subjects showed random-walk distribution. Only two subjects had
resynchronized relative to baseline values at the end of the 3-week post-
bedrest period. The mean BT decreased throughout the study.
This study confirms previous findings indicating that internal
biologic time, more than light/dark cues, is highly important in the
physiology of hypokinesis (for example, BT rhythms). The experimental
desynchronosis observed in the bedrest group and not in the ambulatory
group threatens entrainment to periodic stimuli; therefore, a better
understanding of environmental fluctuations, including social "Zeitge-r
bers," is essential in forestalling a catastrophe of the circadian clock.
The relatively constant phase relationship between HR rhythm and
the light/dark cycle in this study suggests that the HR rhythm is not
an endogenous rhythm but is exogenous. In ambulatory subjects, HR may
be determined largely by the BT rhythm and, thus, may appear to be an
endogenous rhythm. Mills (ref. 3), in his comprehensive review of
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human circadian rhythms, concluded that the rapid adaptation of the HR
rhythm to abnormal time schedules or shifts in sleep and activity sug-
gests that it is not an endogenous rhythm.
The frequency of sampling the plasma pool (for example,. 6 samples/
subject/2^ hours) did not appreciably influence the circadian frequency
of BT and HR rhythms. This seemingly simple demonstration indicates
that both short-term transverse design and the much longer longitudinal
study can be carried out simultaneously and meaningful results can be
derived from both experimental designs.
The results further confirm (ref. 3) that the primary influence of
bedrest on BT and HR periodicity is to reduce the amplitude and change
their phase relationships. The normally entrained rhythms are altered
after approximately 20 days in the hypokinetic environment and are ex-
pressed in changes of amplitude and phases. Bedrest induced low-grade
hypothermia and minor tachycardia. This, according to Selye (ref."U),
is characteristic of acute stress, regardless of the cause of stress.. .
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(a) Data stationary in time.
(b) Amplitude damping with constant phase angle.
Figure 9-2.- Schematic illustrations of certain features encountered in the
construction of summation dials.
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(c) Change in phase angle.
(d) Complete (l80-degree) phase reversal.
Figure 9-2.- Continued.
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(e) A loop, indicating either a linear phase shift or a 26-
hour, rather than a 2U-hour, period.
(f) Small signal-to-noise ratio (random walk).
Figure 9-2.- Continued.
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10. DISSOCIATION OF EFFECTS OF PROLONGED CONFINEMENT AND
BEDREST IN NORMAL HUMAN SUBJECTS; CORTISOL,
INSULIN, THYROXINE, AND TRIIODOTHYRONINE
By Joan Vernikos-Danellis, Ph. D., M. Winget, Ph. D.,
Carolyn S. Leach, Ph. D, and Paul C. Rambaut, Sc. D.
INTRODUCTION
In the same subjects discussed in the previous presentation, endo- •
crine and metabolic information on the relative effects of confinement
and prolonged bedrest was obtained by assaying blood and urine samples
for a variety of parameters. This report is preliminary because only .
the blood changes in cortisol, insulin, thyroxine (T, ), and triiodothy- .
ronine (T ) will be discussed. Furthermore, only the determinations on
the bedrest subjects have been completed, so comparison with the ambula-- •
tory group will not be possible at this time. Eventually, information
on plasma growth hormone, and urinary hormones, and electrolytes' will be
available. Also, the data will be compared to the subjects' own prebedrest
values as well as to those of the ambulatory control group.
DISCUSSION
Urine samples from all subjects were pooled at U-hour intervals,
except during night hours when an 8-hour pool was collected. On days of
bleeding, it-hour pools (150 cubic centimeters maximum) were collected
throughout the 2l*-hour period and stored frozen or cold. No preservatives
were added. At each nine periods throughout the study, five subjects in
each group were bled by repetitive venous punctures every U hours for a
l*8-hour period. The nine periods occurred during two l*8-hour periods
before bedrest; at 10, 20, 30, U2, and 5^ days after confinement to bed;
and at 13 and 20 days after the subjects had become ambulatory again.
Group II subjects were bled on the same schedule as those in group I.
Fifteen cubic centimeters of blood were removed at each bleeding time to
obtain approximately 5 cubic centimeters of plasma and 2.5 cubic centi-
meters of serum. The samples were kept in crushed ice during collection
and separation, frozen promptly, and stored frozen.
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Once during each l+8-hour bleeding period (at 0800 hours on the
second day), hemoglobin, hematocrit, red-blood-cell, and white-blood-cell
parameters were determined in all 12 subjects. No appreciable changes
were observed throughout the study.
Plasma free hydrocortisone levels were determined by Murphy's com-
petitive protein-binding radioassay and expressed as pg/100 cm plasma
o
(ref. l). Serum total thyroxine was expressed as yg/100 cm serum
(ref. 2), and serum triiodothyronine was estimated by determining the
binding capacity of serum to the hormone and was expressed as relative
percent update (ref. 3). Immunoreactive levels of insulin were estimated
by the radioimmunoassay technique of Herbert et al (ref. U). The data
were analyzed by usual statistical techniques and by the method of
Winget et al. (ref. 5).
Several observations made in a previous study (ref. 6) were
confirmed. Diurnal rhythms existed in all four hormone levels during the
prebedrest control period, with hydrocortisone showing a peak at approxi-
mately 0800 hours, and thyroxine and triiodothyronine reaching maximal
levels at 0^ 00 hours. Insulin levels started rising at noon and attained
maximal levels between 2000 hours and midnight and dropped to the lowest
levels at 0^ 00 hours. Between noon and midnight insulin levels were
maintained generally high (fig. l). Lambert and Hoet (ref. 7) have
reported cyclical variations in plasma insulin levels in nonfasting
subjects and found high values occurring at night. On the other hand,
Freinkel et al (ref. 8) used subjects who fasted for 3 or U days.
Insulin was measured either at 0700 to 0800 hours in the morning or at
1500 to 1600 hours in the afternoon, and significantly higher levels
were found in the morning samples. In the present study, meal time and
caloric content were constant throughout. Although the levels of insu-
lin increased dramatically during bedrest (fig. 2) and the time of peak
shifted (fig. l) from midnight to noon and back, the lowest values
always were recorded at OUOO and 0800 hours throughout the study.
The hydrocortisone rhythm was affected little by bedrest. As
mentioned in this symposium, the peak usually occurred at 0800 hours,
anticipating lights on. During bedrest and in the postbedrest period,
a secondary peak at approximately 1600 to 2000 hours was observed in these
subjects (ref. 9) (fig. 3). During the first half of the study, a 50- to
75-percent increase occurred in the mean cortisol level (fig. 2). The
increase was greatest on or about day 20 of bedrest (ref. 10) and was
mostly caused by an increase in the usually low evening and night levels.
Subsequently, these low points returned to normal and decreased to below
control levels by the end of bedrest, A second increase in mean plasma
hydrocortisone occurred after approximately UO days of bedrest. However,
the second increase was caused by a 100-percent increase in the usually
high morning levels. A marked decrease in the amplitude of the steroid
rhythm developed by the end of the study.
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In figure k, a correlation is shown "between the mean 2U-hour prebed-
rest hydrocortisone levels and the mean 2^-hour level during bedrest for
each of the five subjects. Those subjects with lowest initial levels
showed the greatest increase during bedrest and vice versa, as would be
expected according to the negative feedback mechanism regulating the
pituitary/adrenal system.
As had been noted, thyroid rhythms were the least stable • . • . •
(figs. U and 5). The rhythm in either T or T, either disappeared or
showed considerable phase shifting as bedrest progressed and returned
during the postbedrest period. ' .
The increases in mean 2U-hour T levels during bedrest (fig. 2)
were not as evident as in the previous study (ref. 10), but decreases
occurred in both T_ and T« levels during the early part of the study
(10 days, bedrest), confirming earlier observations by C. Leach (ref. ll).
The previously observed sharp rise in T, when the subjects got out of bed
was not evident in this study.
'Recently, Nicoloff et al (ref. 12) have postulated a negative feed-
back action of circulating hydrocortisone in regulating the diurnal
rhythm in thyroid function as measured by thyrodial iodine release and
serum thyroid-stimulating hormone (TSH) values. Their hypothesis was
based on the evidence that pharmacological doses of glucocorticoids'sup-
press- TSH secretion, and a rebound in TSH release follows withdrawal of
the steroid (ref. 13). Although the inverse relationship between adreno-
cortical and overall thyroid function has been demonstrated by several
investigators, the data on which this report was based show a dissocia-
tion between T_, T, , and cortisol rhythmicity caused by bedrest, which
does not support the thesis that the diurnal rhythm in thyroid function
is under corticosteroid regulation.
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Figure 10-1.- Plasma insulin rhythm before, during, and after 56 days of
"bedrest. Stippled areas represent lights off periods. Each point is
the mean of five subjects ± standard error.
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Figure 10-2.- Mean plasma circulating levels of triiodothyronine, thyroxine,
insulin, and cortisol per 2l*-hour period in five subjects before, dur-
ing, and after 56 days of bedrest.
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Figure 10-6.- Serum thyroxine rhythm before, during, and after % days of
bedrest. Stippled areas represent lights off periods. Each point is
the mean of five subjects ± standard error.
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11. NUTRITION AND MUSCULOSKELETAL FUNCTION:
SKYLAB EXPERIMENT SERIES NUMBER MOJO
By Paul C. Rambaut, Sc. D.
INTRODUCTION
Early in 1973, the Skylab Program is scheduled to begin with the
insertion into low earth orbit of the Skylab orbital workshop containing
approximately 10 000 cubic feet of habitable space. One day after the
workshop is established in orbit, it will be joined by an Apollo command
module carrying a crew of three men, including a medical doctor, who
will live and work in space for 28 days. Three months later, this crew
will be followed by another three astronauts, who will occupy the space-
craft for 56 days. The third crew of three men also will occupy the
workshop for 56 days.
The Skylab crewmen will perform a variety of experiments in physics,
astronomy, engineering, and earth resources. Foremost among the experi-
ments that the crewmen will perform are those designed to support the •
medical mission of Skylab. The primary purpose of Skylab is to. obtain.:
precise information on the long-term effects of weightlessness on> physio-
logical and biochemical functions. Unlike any other United States space
mission, Skylab is designed primarily to gather medical information.
For the first time, space-medicine specialists will have the opportunity
to explore, in depth, the subtle changes that have occurred on the
shorter Gemini and Apollo flights.
One of the medical investigations to be pursued intensively'during
the Skylab Program is designed to assess the effects of space flight on
the integrity of bone and muscle. A metabolic-balance study is to be ..
performed to quantitate the effect of space flight on the rate of gain
or loss of key body-chemical constituents. In conjunction with this
study, an exhaustive endocrinological investigation also is being con-
ducted to examine the changes in control functions that accompany or
precipitate changes in body composition and fluid and electrolyte metab-
olism. A series of investigations designed for the study of these
factors has been formally designated as an experiment series entitled
"Nutrition and Musculoskeletal Function" and has been assigned the num-
ber MOJO in the Skylab Program.
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PURPOSE
The M070 experiments are designed for the acquisition of kinetic
data concerning changes in body chemistry as a function of time of expo-
sure to weightless flight. The experiments differ qualitatively from
similar Apollo experiments, which were dependent, for the most part, on
preflight and postflight measurements only.
Alterations in calcium metabolism constitute one of the major threats
to the health of astronauts during long-term exposure to weightlessness
(refs. 1 and 2). Studies of immobilized subjects indicate that the clin-
ical disorders most likely to be encountered during prolonged space flight
are primarily a consequence of an imbalance between bone formation and
resorption. Under these conditions, a loss of skeletal mass occurs,
leading to osteoporosis, hypercalcemia, hypercalciuria, and possibly
nephrolithiasis (refs. 3 and U). Available data from inflight studies
tend to support the use of immobilization as a terrestrial method for
simulation of the alterations in calcium metabolism that occur during
space flight (refs. 5, 6, and 7).
During periods of bedrest lasting from 30 to 36 weeks, calcium
losses from the skeleton average 0.5 percent of total body calcium per
month (ref. 8). Tenfold greater rates of loss from the central portion
of the calcaneus were observed by X-ray transmission scanning (ref. 9).
Mineral loss during bedrest is probably caused by a reduction in the
forces that are applied to the skeleton during normal activity. These
forces would also be absent in the hypogravic environment of space flight.
Therefore, theoretically, loss of bone mineral during space flight is
expected (ref. 10).
PROCEDURES AND HARDWARE
The M070 experiments were designed to obtain definitive information
on the rate of occurrence of these losses in flight. For the experi-
ments , a complete input and output measurement on all Skylab astronauts
will begin 21 days preflight and continue throughout the inflight phase
and for 18 days postflight. All nutrient and water intake will be meas-
ured precisely. All fecal material and urine samples will be returned
to earth for analysis, and samples of blood will be taken preflight,
inflight, and postflight.
The M070 experiments will be the most rigorous metabolic studies
ever conducted in manned space flight and are among the prime objectives
of the mission. However, a secondary program objective of Skylab is to
test the environmental conditions thought to be necessary to optimize
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psychological performance of the crewmen. As a design goal, the Skylab
spacecraft is to be made so pleasant a living and working environment
that the crewmen will be reluctant to leave it. Therefore, two conflict-
ing goals were presented to spacecraft designers. One was to design
equipment to support an intensive metabolic investigation, and the other
was to design equipment that was to make the spacecraft as habitable as
the technology permitted.
SKYLAB FOOD SYSTEM
Foremost among the conditions of life known to influence behavior
is the type and variety of the food system. The food system to be em-
ployed in Skylab is composed basically of 72 different food items. These
items are packed in flip-top cans and include a variety of frozen, ther-
mostabilized, dehydrated, and compressed foods. A facility exists on
Skylab to heat some foods before consumption and to refrigerate others.
The energy requirements of each astronaut are estimated on the basis
of his age and body weight and are adjusted for some of the known effects
of weightless flight. Individualized menus are formulated and offered
to the crewmen for a series of 5- or 6-day metabolic test periods. After
several iterations of this testing program, menus are finalized for
flight. A number of nutrients are controlled within rigid day-to-day
tolerances, as depicted in table I.
Menus are designed according to 6-day cycles. The menus contain a
core set of foods that provide the required levels of nitrogen, calcium,
phosphorus, magnesium, potassium, and sodium. This core diet is approxi-
mately 12.552 joules (300 kilocalories) less than the caloric requirement
established for one-g. All additional calories are provided by food items
that are low enough in controllable elements so they will not perturb
the prescribed intake ranges. The items that furnish the additional
calories are termed empty-calorie items.
The crewmen will be encouraged to consume completely the items on
their nominal menus. A system of negative reporting will be employed so
that the crewmen will report, at the end of each day, any deviation from
the nominal menu. The only permissible deviations are the imcomplete
consumption or omission of an item on the nominal menu, the use of an
off-nominal rehydration quantity, or the consumption of empty-calorie
items.
To maintain controlled intakes of calcium, phosphorus, magnesium,
sodium, and potassium in conjunction with these possible deviations, the
crewmembers also are supplied with a series of mineral supplements. By
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the use of the supplements, the intake of each of these elements can be
adjusted independently of the others. The mineral supplements are listed
in table II. A computer program has been designed to calculate mineral
and caloric deficits from information transmitted to earth by the crew.
The quantity of mineral supplements equivalent to its deficit is eval-
uated in near real time and transmitted back to trie crew.
The food system utilized for the Skylab Program is not only designed
to meet the requirements and the constraints imposed by metabolic and
psychological demands of the crewmembers and the demands of medical
experimenters, but it is also designed to withstand the physical and
environmental characteristics of the vehicle during prelaunch, test,
launch, orbit, and entry periods.
The microbiological composition of the foods complies with the re,-
quirad specifications (ref. ll). Each Skylab food item is analyzed for
approximately 30 nutrients. These analyses are performed as the food is
produced and after various periods of storage. In addition, information
on the effect that heating, in the Skylab heater tray, has on the nutri-
ents of interest is acquired.
The total supply of water for the entire mission will be launched in
the orbital workshop. The water system provides the capability to supply
and dispense water for food and beverage preparation and drinking with
an accuracy of +1 percent. The system also incorporates a capability
to dispense and maintain an iodine biocide to ensure" microbial control.
A separate drink dispenser is provided for each crewman, and this dis-
penser contains a visual indication of the amount of water dispensed.
The water that the crewman ingests is essentially free of calcium,
magnesium, phosphorus, nitrogen, potassium, or sodium.
MASS-MEASUREMENT DEVICES
To measure mass in a weightless environment, a device is employed
that measures and records the time associated with the period of a pendu-
lum with a fixed displacement from a spring-supported restoring force.
The masses to be measured are accelerated uniformally by this repeatable
restoring force, and three periods of the pendulum are timed. Known
masses are measured, and a nomograph is developed that can be used to
determine the mass of other objects. This minimal response to gravita-
tional force of the device is eliminated in orbital flight by recalibra-
tion with the same known masses that were used preflight. The difference
is that the oscillating period which results between different masses is
timed by interruption of a light train. A knife-edge device attached to
the oscillating system intermittently cuts the light train, triggering a
timing circuit in the mass-measurement device electronic subsystem. This
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time is-converted and presented in millisecond units. The display pro-
vides a six-digit readout. The linear spring oscillating arrangement is
sufficiently responsive to small changes in mass to permit accurate dis-
crimination over the expected range of mass, Temperature sensing of the
springs is important to correct for thermal effects. A thermometer was
incorporated to sense and digitally display the temperature of a thermal
pathway, related to spring temperature. Correction values for tempera-
ture effects have been developed during one-g calibration.
Two types of mass measurement device are placed on board the space-
craft. One device will accommodate small masses up to 1 kilogram, and
the other large enough to measure the mass of an astronaut.
WASTE MANAGEMENT SYSTEM
At a temperature below 288.15° K (59° F), the Skylab waste management
system (WMS) provides for the collection, processing, storage, and disposal
of feces, urine, and vomitus. It is designed to preclude mixing and cross-
contamination of samples of urine, feces, vomit, and debris of the crew-
members and also prevents cross-contamination in excess of 1 percent
between samples from the same crewmember obtained on different days.
The WMS also provides the capability for transferring processed and iden-
tified samples of the collected urine, feces, and vomitus through the
command module for subsequent return to earth for analysis.
Urine is collected in a device called the centrifugal urine sep-
arator assembly (CUSA). The CUSA permits urine from each micturition to
be drawn into a centrifuge inlet line by means of entrained air from a
downstream blower. The liquid is carried by centrifugal force to the
outer diameter of a drum that is rotating at approximately 250 rpm. The
rotating annulus of the urine impinges on a stationary pitot head, and a
dynamic force pumps the liquid through the outlet line to an external
urine-bladder collector assembly. The urine receiver completely encloses
the urine stream during the collection process. The urine collector pro-
vides the capability to extract representative samples of 122 cubic centi-
meters from a homogeneous pool'for freezing. The samples are frozen to
below 25^ .00° K (-2.5° F) at the end of each 2U-hour period. The urine-
collection unit determines the volume of each 2l*-hour void to an accuracy
of ±2 percent. A flushing capability is provided as a means of control-
ling cross-contamination between the 2^ -hour pooled urine collections for
each user. Use of a flushing system limits the day-to-day cross-
contamination between urine samples to less than 1 percent of the volume
collected each day.
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The 2h-hour urine pool normally is maintained at a temperature be-
low 288.15° K (59° F), and the temperature of this pool does not exceed
288.15° K (59° F) for more than an accumulated time of 3 hours during
any 2U-hour period. The urine collection system interfaces with the
command module for transferring, collecting, measuring, and sampling of
urine collected during the command module operations before the orbital
workshop activation.
A lithium chloride tracer is incorporated as a backup method to
determine the volume of urine collected in each 2^-hour urine pooling
period. Lithium is added in the amount of 30 ± 0.3 milligrams into each
pooling bag before flight. The primary mode of volume determinations
depends on displacement of a pressure plate with a calibrated readout.
A contingency urine system also exists that utilizes the Apollo-type
roll-on cuff and adaptors to accommodate urine collection directly into
the urine-collection bags without the use of air entrainment. After
each void, the urine collection bags would be stored, employing the
chilling capability of the urine collector. Volume measurement will be
accomplished by using the lithium chloride tracer. The contingency col-
lection system also provides the capability for extracting urine samples.
The fecal waste processor provides for vacuum drying of fecal and
vomitus collections before long-term storage.
ERROR ANALYSIS
An error analysis is being conducted on the M070 experiments to
assess the effect that changes in design could have on the ultimate
sensitivity of the experiments. As currently conceived, it is expected
that the experiments will be'able to detect, at the two-sigma level of
confidence, changes as small as 5 percent in the body pool of calcium at
the end of a 56-day period.
A mathematical model of the M070 experiments is being formulated
and will incorporate each component of the experiment design and opera-
tion that can contribute to error. This model will be used to predict
the effect of changes in any item of equipment or any mode of operation.
BLOOD COLLECTION AND EQUIPMENT
Blood samples will be collected inflight with the aid of a specially
designed sampling device that will return approximately 11 cubic centi-
meters of plasma in a frozen state for ground-based analysis.
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PREFLIGHT AND POSTFLIGHT METABOLIC CONTROL PERIODS
Metabolic control periods vill be conducted for 21 days preflight
and for 18 days postflight. During these periods, the crewmen will con-
sume Skylab flight foods that will be supplemented, to a minor extent,
with fresh food items to improve the acceptability of the flight diet.
Complete collections will be made using a portable biological specimen
kit that will enable the crewmember to collect urine and fecal samples
and preserve them in a frozen state until they are returned to the labo-
ratory for analysis.
BASELINE STUDIES
A variety of ground-based controlled .studies have been conducted to
determine the effect of various experimental variables other than weight-
lessness on the parameters of interest. To assess the effect of immobil-
ization and hypogravia, the effect of long-term recumbency has been
extensively studied. The effect of varying intakes of protein and of
calcium and magnesium on the parameters of interest has been investi-
gated, and the influence of different activity levels on mineral balance
has been studied.
These baseline studies culminate in a 56-day manned chamber study
that is designated the Skylab medical experiments altitude test (SMEAT).'
SMEAT is a highly-fidelity mockup of Skylab in which three crewmembers
will be confined for 56 days and in which all Skylab medical experiments,
including MOTO, will be performed in a manner as similar as possible to
the way in which they will be performed in flight. Like Skylab, SMEAT
has an atmosphere consisting of 70 percent oxygen and 30 percent nitro-
o
gen, 3^ 1*73.785 N/m (5 psi). It contains carbon dioxide at a partial
pressure of 5 millimeters of mercury. Primarily, the concern for this
relatively high carbon dioxide partial pressure was the reason for con-
ducting SMEAT before Skylab.
LABORATORY ANALYSIS
All fecal, urine, and blood samples from both SMEAT and Skylab will
be returned to the NASA Manned Spacecraft Center for analysis. Extensive
tests have been undertaken to establish the precise laboratory errors
that are introduced in the analysis of these samples, as well as errors
arising from any degradation that may have occurred in the constituents
during prolonged storage in space and on the ground.
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CONCLUSION
The MOTO experiments are expected to give medical investigators
precise information on a variety of biochemical changes occurring during
exposure to space flight. Sufficient control data are "being generated
by baseline studies to differentiate those effects that are caused by
weightless flight and those that are caused by other abnormal conditions
that normally accompany spaceflight. However, some environmental con-
ditions remain uncontrolled. For instance, fairly severe shifts in
sleep cycles possibly will be necessitated by factors associated with
the nature of the Skylab orbit. The unknown interaction of these factors
with the physiological changes that the M070 experiments are designed to
detect will introduce errors of unknown proportions. Nevertheless, the
M0?0 experiments will provide essential data on which decisions will be
based concerning the qualification of man, first on Skylab III and IV and
then on missions of much longer duration.
The MOJO and other Skylab experiments will eventually provide an
answer for the question of whether man can live indefinitely in weightless
flight. If physiological degradation appears to be severe under these
conditions, then a new era of space medicine will evolve for the develop-
ment of countermeasures to the deteriorative effects of weightless flight.
Such countermeasures will be specific devices or procedures tailored to
preclude the occurrence of one or more physiological difficulties.
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TABLE 11-I.- CONTROLLED-NUTRIENT DATA
Nutrient
Calcium
Protein
Phosphorus
Sodium
Magnesium
Potassium
Intake range
750 to 850 mg
90 to 125 gr
1500 to 1TOO mg
3000 to 6000 mg
300 to HOO mg
At least 39^ 5 mg
Tolerance
±l6 mg
±10 gr
±120 mg
±500 mg
±100 mg
—
TABLE 11-11.- MINERAL-SUPPLEMENT DATA
Mineral
supplement
Calcium lactate
Orthophosphate
Magnesium lactate
Sodium chloride
Potassium gluconate
Controllable
element
Calcium
Phosphorus
Magnesium
Sodium
Potassium
Amount of
element, mg
32
110
25
197
195-5
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